<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving
and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.2" article-type="other">
  <front>
    <article-meta>
      <title-group>
        <article-title>A Randomized Trial of Rectal Indomethacin to Prevent
Post-ERCP Pancreatitis</article-title>
        <subtitle>Reproduction</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>B. Joseph Elmunzer</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>B. Joseph Elmunzer, M.D.</string-name>
          <role vocab="https://credit.niso.org" vocab-term="writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">writing</role>
          <xref ref-type="aff" rid="aff-1">a</xref>
          <xref ref-type="corresp" rid="cor-1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>James M. Scheiman</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>James M. Scheiman, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Glen A. Lehman</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Glen A. Lehman, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Amitabh Chak</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Amitabh Chak, M.D.</string-name>
          <xref ref-type="aff" rid="aff-3">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Patrick Mosler</surname>
            <given-names>Ph.D.</given-names>
          </name>
          <string-name>Patrick Mosler, M.D., Ph.D.</string-name>
          <xref ref-type="aff" rid="aff-4">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-1602-4341</contrib-id>
          <name>
            <surname>Peter D. R. Higgins</surname>
            <given-names>Ph.D.</given-names>
          </name>
          <string-name>Peter D.R. Higgins, M.D., Ph.D.</string-name>
          <email>phiggins@umich.edu</email>
          <xref ref-type="aff" rid="aff-1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodney A. Hayward</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Rodney A. Hayward, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joseph Romagnuolo</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Joseph Romagnuolo, M.D.</string-name>
          <xref ref-type="aff" rid="aff-5">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grace H. Elta</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Grace H. Elta, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stuart Sherman</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Stuart Sherman, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Akbar K. Waljee</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Akbar K. Waljee, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aparna Repaka</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Aparna Repaka, M.D.</string-name>
          <xref ref-type="aff" rid="aff-3">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matthew R. Atkinson</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Matthew R. Atkinson, M.D.</string-name>
          <xref ref-type="aff" rid="aff-3">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gregory A. Cote</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Gregory A. Cote, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Richard S. Kwon</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Richard S. Kwon, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee McHenry</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Lee McHenry, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cyrus R. Piraka</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Cyrus R. Piraka, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Erik J. Wamsteker</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Erik J. Wamsteker, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>James L. Watkins</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>James L. Watkins, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sheryl J. Korsnes</surname>
            <given-names>M. A.</given-names>
          </name>
          <string-name>Sheryl J. Korsnes, M.A.</string-name>
          <xref ref-type="aff" rid="aff-1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suzette E. Schmidt</surname>
            <given-names>C. C. R. P.</given-names>
          </name>
          <string-name>Suzette E. Schmidt, B.S.N., C.C.R.P.</string-name>
          <xref ref-type="aff" rid="aff-2">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sarah M. Turner</surname>
            <given-names>B. S.</given-names>
          </name>
          <string-name>Sarah M. Turner, B.S.</string-name>
          <xref ref-type="aff" rid="aff-4">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sylvia Nicholson</surname>
            <given-names>C. C. R. C.</given-names>
          </name>
          <string-name>Sylvia Nicholson, C.C.R.C.</string-name>
          <xref ref-type="aff" rid="aff-4">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Evan L. Fogel</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Evan L. Fogel, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2">b</xref>
        </contrib>
      </contrib-group>
      <aff id="aff-1">
        <institution-wrap>
          <institution>University of Michigan Medical Center</institution>
        </institution-wrap>
      </aff>
      <aff id="aff-2">
        <institution-wrap>
          <institution>Indiana University Medical Center</institution>
        </institution-wrap>
      </aff>
      <aff id="aff-3">
        <institution-wrap>
          <institution>University Hospitals Case Medical Center</institution>
        </institution-wrap>
      </aff>
      <aff id="aff-4">
        <institution-wrap>
          <institution>University of Kentucky Medical Center</institution>
        </institution-wrap>
      </aff>
      <aff id="aff-5">
        <institution-wrap>
          <institution>Medical University of South Carolina</institution>
        </institution-wrap>
      </aff>
      <author-notes>
        <corresp id="cor-1"/>
      </author-notes>
      <history/>
      <abstract>
        <p><bold>BACKGROUND</bold> Preliminary research suggests that rectally
administered nonsteroidal antiinflammatory drugs may reduce the
incidence of pancreatitis after endoscopic retrograde
cholangiopancreatography (ERCP).</p>
        <p><bold>METHODS</bold> In this multicenter, randomized,
placebo-controlled, double-blind clinical trial, we assigned patients at
elevated risk for post-ERCP pancreatitis to receive a single dose of
rectal indomethacin or placebo immediately after ERCP. Patients were
determined to be at high risk on the basis of validated patient- and
procedure-related risk factors. The primary outcome was post-ERCP
pancreatitis, which was defined as new upper abdominal pain, an
elevation in pancreatic enzymes to at least three times the upper limit
of the normal range 24 hours after the procedure, and hospitalization
for at least 2 nights.</p>
        <p><bold>RESULTS</bold> A total of 602 patients were enrolled and
completed follow-up. The majority of patients (82%) had a clinical
suspicion of sphincter of Oddi dysfunction. Post-ERCP pancreatitis
developed in 27 of 295 patients (9.2%) in the indomethacin group and in
52 of 307 patients (16.9%) in the placebo group (P=0.005).
Moderate-to-severe pancreatitis developed in 13 patients (4.4%) in the
indomethacin group and in 27 patients (8.8%) in the placebo group
(P=0.03).</p>
        <p><bold>CONCLUSIONS</bold> Among patients at high risk for post-ERCP
pancreatitis, rectal indomethacin significantly reduced the incidence of
the condition. (Funded by the National Institutes of Health;
ClinicalTrials.gov number, NCT00820612. opens in new tab.)</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <boxed-text>
      <p>
        <bold>Important</bold>
      </p>
      <p>This is a Quarto reproduction of a paper published in the New England
Journal of Medicine in 2012, which you can find at
<ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/full/10.1056/NEJMoa1111103">https://www.nejm.org/doi/full/10.1056/NEJMoa1111103</ext-link>.
Some of the reproduction code was provided by Peter Higgins.</p>
    </boxed-text>
    <p>Acute pancreatitis is the most common major complication of
endoscopic retrograde cholangiopancreatography
(ERCP),(<xref alt="Martin L. Freeman and Guda 2004" rid="ref-freeman2004" ref-type="bibr">Martin
L. Freeman and Guda 2004</xref>) accounting for substantial morbidity,
occasional death, and estimated health care expenditures of
approximately $150 million annually in the United
States.(<xref alt="Martin L. Freeman et al. 1996" rid="ref-freeman1996" ref-type="bibr">Martin
L. Freeman et al. 1996</xref>;
<xref alt="HCUPnet 2019" rid="ref-hcupnet2019utilization" ref-type="bibr">HCUPnet
2019</xref>) Given the magnitude of this problem, more than 35
pharmacologic agents have been studied for the prophylaxis of post-ERCP
pancreatitis, and many prospective clinical trials addressing
chemoprevention have been conducted. To date, however, no medication has
proved to be consistently effective in preventing post-ERCP pancreatitis
on the basis of data from high-quality clinical trials, and no
pharmacologic prophylaxis for post-ERCP pancreatitis is in widespread
clinical use.</p>
    <p>Nonsteroidal antiinflammatory drugs (NSAIDs) are potent inhibitors of
phospholipase A2, cyclooxygenase, and neutrophil–endothelial
interactions, all believed to play an important role in the pathogenesis
of acute
pancreatitis.(<xref alt="Gross et al. 1993" rid="ref-gross1993inflammatory" ref-type="bibr">Gross
et al. 1993</xref>;
<xref alt="Mäkelä, Kuusi, and Schröder 1997" rid="ref-makela1997inhibition" ref-type="bibr">Mäkelä,
Kuusi, and Schröder 1997</xref>) NSAIDs are inexpensive and easily
administered and have a favorable risk profile when given as a single
dose, making them an attractive option in the prevention of post-ERCP
pancreatitis. Preliminary studies evaluating the protective effects of
single-dose rectal indomethacin or diclofenac in post-ERCP pancreatitis
have been
conducted,(<xref alt="Murray et al. 2003" rid="ref-murray2003diclofenac" ref-type="bibr">Murray
et al. 2003</xref>;
<xref alt="Sotoudehmanesh et al. 2007" rid="ref-sotoudehmanesh2007indomethacin" ref-type="bibr">Sotoudehmanesh
et al. 2007</xref>;
<xref alt="Khoshbaten et al. 2008" rid="ref-khoshbaten2008role" ref-type="bibr">Khoshbaten
et al. 2008</xref>;
<xref alt="JE et al. 2007" rid="ref-je2007effect" ref-type="bibr">JE et
al. 2007</xref>) and a meta-analysis suggests
benefit.(<xref alt="Elmunzer et al. 2008" rid="ref-elmunzer2008" ref-type="bibr">Elmunzer
et al. 2008</xref>)</p>
    <p>Despite these data, rectal NSAIDs are seldom used in clinical
practice because there is no conclusive evidence from randomized,
controlled
trials(<xref alt="Dumonceau et al. 2010" rid="ref-dumonceau2010" ref-type="bibr">Dumonceau
et al. 2010</xref>) and because previous positive meta-analyses of other
agents for the prevention of post-ERCP pancreatitis have been disproved
by further
investigation.(<xref alt="Andriulli et al. 2000" rid="ref-andriulli2000" ref-type="bibr">Andriulli
et al. 2000</xref>,
<xref alt="2007" rid="ref-andriulli2007" ref-type="bibr">2007</xref>)
Moreover, it remains unclear whether NSAIDs provide incremental benefit
over temporary pancreatic stents, the only proven prophylactic
intervention for post-ERCP
pancreatitis.(<xref alt="Tarnasky et al. 1998" rid="ref-tarnasky1998" ref-type="bibr">Tarnasky
et al. 1998</xref>;
<xref alt="Fazel et al. 2003" rid="ref-fazel2003" ref-type="bibr">Fazel
et al. 2003</xref>;
<xref alt="Singh et al. 2004" rid="ref-singh2004" ref-type="bibr">Singh
et al. 2004</xref>) Therefore, we conducted a multicenter, randomized,
controlled clinical trial to evaluate the efficacy of prophylactic
rectal indomethacin for the prevention of post-ERCP pancreatitis in
high-risk patients.</p>
    <sec id="methods">
      <title>Methods</title>
      <sec id="study-design">
        <title>Study design</title>
        <p>We enrolled patients at four university-affiliated medical
    centers in the United States after approval from the human studies
    review committee at each institution. An independent data and safety
    monitoring board provided regulatory oversight by reviewing blinded
    subject data quarterly and conducting the a priori scheduled interim
    analysis. The complete study
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_protocol.pdf"><bold>protocol</bold></ext-link>
    is available with the full text of this article at NEJM.org.</p>
      </sec>
      <sec id="patients">
        <title>Patients</title>
        <p>The inclusion criteria selected patients with an elevated
    baseline risk of post-ERCP pancreatitis on the basis of
    prospectively validated patient- and procedure-related independent
    risk
    factors.(<xref alt="Martin L. Freeman 2007" rid="ref-freeman2007" ref-type="bibr">Martin
    L. Freeman 2007</xref>) Patients were eligible if they met one or
    more of the following major criteria: clinical suspicion of
    sphincter of Oddi dysfunction (as defined in the
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_appendix.pdf"><bold>Supplementary
    Appendix</bold></ext-link>, available at NEJM.org), a history of
    post-ERCP pancreatitis, pancreatic sphincterotomy, precut
    sphincterotomy (a procedure performed to facilitate biliary access
    when standard cannulation techniques are unsuccessful), more than
    eight cannulation attempts (as determined by the endoscopist),
    pneumatic dilatation of an intact biliary sphincter, or
    ampullectomy. Patients were also eligible for inclusion if they met
    two or more of the following minor criteria: an age of less than 50
    years and female sex, a history of recurrent pancreatitis
    (<inline-formula><alternatives><tex-math><![CDATA[\ge]]></tex-math><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:mo>≥</mml:mo></mml:math></alternatives></inline-formula>
    2 episodes), three or more injections of contrast agent into the
    pancreatic duct with at least one injection to the tail of the
    pancreas, excessive injection of contrast agent into the pancreatic
    duct resulting in opacification of pancreatic acini, or the
    acquisition of a cytologic specimen from the pancreatic duct with
    the use of a brush.</p>
        <p>The exclusion criteria are listed in the
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_appendix.pdf"><bold>Supplementary
    Appendix</bold></ext-link> and were intended to exclude patients in
    whom ERCP was unsuitable and those who had active pancreatitis, had
    a contraindication to the use of NSAIDs (e.g., creatinine level,
    &gt;1.4 mg per deciliter [124 <inline-formula><alternatives><tex-math><![CDATA[\mu]]></tex-math><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>mol
    per liter] or active peptic ulcer disease), were already taking
    NSAIDs (other than cardioprotective aspirin), or had an anticipated
    low risk of post-ERCP pancreatitis (e.g., those with chronic
    calcific pancreatitis or a pancreatic-head mass or those undergoing
    routine biliary-stent exchange).</p>
        <p>Eligible patients who provided written informed consent underwent
    randomization at the conclusion of the ERCP procedure, because
    patients without risk factors could be included in the study on the
    basis of procedure-related factors alone.</p>
      </sec>
      <sec id="intervention">
        <title>Intervention</title>
        <p>All procedure-related interventions were dictated by the
    performing endoscopist. Immediately after the procedure, if the
    endoscopist and research coordinator determined that inclusion
    criteria had been met, patients were randomly assigned to receive
    either two 50-mg indomethacin suppositories or two
    identical-appearing placebo suppositories. The randomization
    schedule, which was stratified according to study center, was
    generated centrally at the University of Michigan.</p>
        <p>The suppositories were administered immediately after ERCP while
    the patient was still in the procedure room. The rectal route was
    selected on the basis of available pilot data suggesting that only
    rectal NSAIDs are effective in preventing post-ERCP pancreatitis,
    perhaps owing to more rapid and complete bioavailability than with
    oral
    administration.(<xref alt="Elmunzer et al. 2008" rid="ref-elmunzer2008" ref-type="bibr">Elmunzer
    et al. 2008</xref>;
    <xref alt="Marel et al. 2004" rid="ref-vandermarel2004" ref-type="bibr">Marel
    et al. 2004</xref>) The indomethacin suppositories were purchased
    from two vendors: G&amp;W Laboratories and Custom Med Apothecary.
    Formal potency testing confirmed that the vendors provided
    indomethacin suppositories that were pharmacodynamically equivalent
    (Analytic Research Laboratories).</p>
      </sec>
      <sec id="outcomes">
        <title>Outcomes</title>
        <p>The primary outcome of the study was the development of post-ERCP
    pancreatitis, which was defined according to consensus
    criteria(<xref alt="Cotton et al. 1991" rid="ref-cotton1991" ref-type="bibr">Cotton
    et al. 1991</xref>) (details are provided in the
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_appendix.pdf"><bold>Supplementary
    Appendix</bold></ext-link>). Briefly, post-ERCP pancreatitis was
    diagnosed if there was a new onset of pain in the upper abdomen, an
    elevation in pancreatic enzymes of at least three times the upper
    limit of the normal range 24 hours after the procedure, and
    hospitalization for at least 2 nights. The secondary outcome was the
    development of moderate or severe post-ERCP pancreatitis (see the
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_appendix.pdf"><bold>Supplementary
    Appendix</bold></ext-link>). Data regarding the length of hospital
    stay for patients with post-ERCP pancreatitis were collected
    prospectively, but the duration of hospitalization was not a
    prespecified outcome measure and was therefore analyzed post
    hoc.</p>
        <p>Patients were observed in the recovery area for at least 90
    minutes after the procedure. Patients in whom abdominal pain
    developed during this observation period were admitted to the
    hospital (or for current inpatients, kept in the hospital).
    Decisions regarding evaluation of complications after the procedure
    and in-hospital care were left to the discretion of the endoscopist
    and clinical-service staff members, who were unaware of study-group
    assignments. Serum amylase and lipase were measured in hospitalized
    patients at least once 24 hours after the procedure and subsequently
    at clinical discretion.</p>
        <p>Patients who were discharged after an uneventful ERCP were
    contacted by telephone within 5 days to capture delayed occurrence
    of the primary end point. Patients were again contacted at 30 days
    to assess for delayed adverse events and to determine the severity
    of post-ERCP pancreatitis, which was defined in part by the length
    of hospitalization for pancreatitis. The original study protocol
    stated that the primary end point would be assessed within 48 hours
    after the procedure. Although post-ERCP pancreatitis generally
    occurs within this period, we contacted patients up to 5 days after
    ERCP to ensure capture of delayed cases of the primary end
    point.</p>
        <p>Patient demographics, risk factors, ERCP procedural elements, and
    follow-up data were recorded on standardized data-collection forms
    by an investigator or coordinator who was unaware of study-group
    assignments. All data were subsequently entered into a Web-based
    database, Velos eResearch, and managed by an independent
    data-management service.</p>
      </sec>
      <sec id="adverse-events">
        <title>Adverse events</title>
        <p>Adverse events were defined as reported
    previously.(<xref alt="Cotton et al. 1991" rid="ref-cotton1991" ref-type="bibr">Cotton
    et al. 1991</xref>;
    <xref alt="Mallery et al. 2003" rid="ref-mallery2003" ref-type="bibr">Mallery
    et al. 2003</xref>) Any cases of post-ERCP pancreatitis, other
    complications of the procedure, and adverse events that were
    potentially attributable to the study drug were reported to the
    local institutional review board and the data and safety monitoring
    board. These reportable adverse events were gastrointestinal
    bleeding, perforation, infection, renal failure, allergic reaction,
    myocardial infarction, cerebrovascular accident, and death.</p>
      </sec>
      <sec id="statistical-analysis">
        <title>Statistical analysis</title>
        <p>The prophylactic placement of pancreatic stents has been shown to
    reduce the rate of post-ERCP pancreatitis to 5 to 10% among
    high-risk
    patients.(<xref alt="Tarnasky et al. 1998" rid="ref-tarnasky1998" ref-type="bibr">Tarnasky
    et al. 1998</xref>;
    <xref alt="Fazel et al. 2003" rid="ref-fazel2003" ref-type="bibr">Fazel
    et al. 2003</xref>;
    <xref alt="Singh et al. 2004" rid="ref-singh2004" ref-type="bibr">Singh
    et al. 2004</xref>) An internal audit of high-risk ERCPs at
    participating institutions revealed a post-ERCP rate of pancreatitis
    of approximately 10%, despite routine prophylactic stent placement
    in appropriate patients. We estimated that 948 patients (474 per
    study group) would provide a power of at least 80% to detect a 50%
    reduction in the incidence of post-ERCP pancreatitis, from 10% in
    the placebo group to 5% in the indomethacin group, on the basis of
    Fisher’s exact test, with a two-sided significance level of
    0.05.</p>
        <p>For the analysis of the primary end point, we used a two-tailed
    Fisher’s exact test to analyze the difference in the proportion of
    patients with post-ERCP pancreatitis in the indomethacin group and
    the placebo group, with a final two-sided P value of less than 0.041
    indicating statistical significance. This P value reflects the
    partial spending of degrees of freedom of statistical testing that
    resulted from conducting two interim analyses on the basis of the
    O’Brien–Fleming approach and the Lan–DeMets alpha spending function.
    Results for the primary end point were reported in terms of absolute
    and relative risk reduction. The secondary end point, the proportion
    of patients with moderate or severe post-ERCP pancreatitis in each
    study group, was similarly calculated, with a P value of less than
    0.05 indicating statistical significance. Hospital length of stay
    was found to have a skewed distribution, and therefore we used the
    Kruskal–Wallis equality-of-populations rank test to compare median
    values.</p>
        <p>When information for the first 400 patients could be evaluated,
    an ad hoc rule was used to trigger an interim analysis by the data
    and safety monitoring board: if more than 66% of cases of
    pancreatitis or bleeding were in a particular study group, a formal
    comparison between groups would be performed with the use of a
    two-sided stopping boundary of 0.005. On the basis of the results of
    the first analysis, the data and safety monitoring board recommended
    a second interim analysis after an additional 200 patients were
    enrolled.</p>
        <p>According to a previously proposed framework for evaluating the
    heterogeneity in treatment effects on the primary end
    point,(<xref alt="Kent et al. 2010" rid="ref-kent2010" ref-type="bibr">Kent
    et al. 2010</xref>) a post hoc analysis (not described in the
    protocol) was performed on data from enrolled patients according to
    their pretreatment risk of post-ERCP pancreatitis. In this analysis,
    we assessed whether the relative treatment effect was consistent
    across the spectrum of risk of post-ERCP pancreatitis. Individual
    patient risk scores were determined by assigning one point for each
    major inclusion criterion and 0.5 points for each minor inclusion
    criterion.</p>
        <p>We performed additional exploratory subgroup analyses on the
    following prespecified characteristics: age, sex, suspicion of
    sphincter of Oddi dysfunction, a history of post-ERCP pancreatitis,
    a history of recurrent pancreatitis, sphincter of Oddi dysfunction
    as documented on manometry, more than eight cannulation attempts,
    precut sphincterotomy, pancreatic sphincterotomy, pancreatic
    acinarization, biliary sphincterotomy, ampullectomy, placement of a
    pancreatic stent, and trainee involvement in the ERCP. We performed
    additional post hoc subgroup analyses on the type of sphincter of
    Oddi dysfunction, inpatient versus outpatient status, and
    participating medical center. All subgroup statistical analyses were
    evaluated for interaction effects with indomethacin by testing for
    significance of a corresponding interaction term in a multiple
    logistic-regression
    model.(<xref alt="Kent et al. 2010" rid="ref-kent2010" ref-type="bibr">Kent
    et al. 2010</xref>)</p>
      </sec>
    </sec>
    <sec id="results">
      <title>Results</title>
      <sec id="patients-1">
        <title>Patients</title>
        <p>From February 2009 through July 2011, a total of 602 subjects
    were enrolled
    (<xref alt="Figure 1" rid="fig-enrollment-outcomes">Figure 1</xref>).
    In July 2011, the data and safety monitoring board performed an
    interim analysis to assess the outcomes of the first 600 patients
    and recommended that the study be terminated early on the basis of
    the benefit of indomethacin as compared with placebo. Thus, we
    terminated the study according to the a priori stopping rule.</p>
        <fig id="fig-enrollment-outcomes">
          <caption>
            <p>Figure 1: Enrollment and Outcomes.</p>
          </caption>
          <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/notebooks-consort-fig-enrollment-outcomes-output-2.png"/>
        </fig>
        <p>A total of 295 patients received indomethacin, and 307 patients
    received placebo. One patient in the indomethacin group could not
    retain the suppositories but was included in the intention-to-treat
    analysis. Follow-up of all patients for the primary and secondary
    end points was complete
    (<xref alt="Figure 1" rid="fig-enrollment-outcomes">Figure 1</xref>).
    Baseline characteristics were similar in the two study groups
    (<xref alt="Table 1" rid="tbl-characteristics-baseline">Table 1</xref>).
    Notably, 82.2% of patients had a clinical suspicion of sphincter of
    Oddi dysfunction.</p>
        <fig id="tbl-characteristics-baseline">
          <caption>
            <p>Table 1: Characteristics of the Patients at
      Baseline.</p>
          </caption>
        </fig>
      </sec>
      <sec id="study-outcomes">
        <title>Study outcomes</title>
        <p>The primary outcome of post-ERCP pancreatitis occurred in 79 of
    602 patients (13.1%). Of these events, 27 of 295 (9.2%) occurred in
    the indomethacin group and 52 of 307 (16.9%) occurred in the placebo
    group (P=0.005), corresponding to an absolute risk reduction of 7.7
    percentage points (number needed to treat [NNT] to prevent one
    episode of post-ERCP pancreatitis, 13) and a relative risk reduction
    of 46%
    (<xref alt="Figure 2" rid="fig-incidences-adverse-events">Figure 2</xref>).</p>
        <fig id="fig-incidences-adverse-events">
          <caption>
            <p>Figure 2: Incidence of the Primary and Secondary End
      Points and Adverse Events</p>
          </caption>
          <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/notebooks-incidences-fig-incidences-adverse-events-output-1.png"/>
        </fig>
        <p>All 79 patients with post-ERCP pancreatitis completed the 30-day
    follow-up necessary to determine the severity of post-ERCP
    pancreatitis. The secondary outcome of moderate or severe post-ERCP
    pancreatitis occurred in 40 patients: 13 (4.4%) in the indomethacin
    group and 27 (8.8%) in the placebo group (P=0.03)
    (<xref alt="Figure 2" rid="fig-incidences-adverse-events">Figure 2</xref>).
    Three patients in each group had severe post-ERCP pancreatitis, and
    one patient in the placebo group had pancreatic necrosis.</p>
        <p>Among patients with post-ERCP pancreatitis, the median length of
    hospital stay was 0.5 days shorter in the indomethacin group than in
    the placebo group (3.5 vs. 4.0 days, P&lt;0.001).</p>
        <sec id="heterogeneity-in-treatment-effects">
          <title>Heterogeneity in Treatment Effects</title>
          <p>The relative benefit of indomethacin did not vary significantly
      according to patients’ pretreatment risk score, although the
      absolute risk reduction varied from an NNT of 21 for those with a
      risk score of 1 (one major or two minor inclusion criteria) to an
      NNT of 6 for those with a risk score of 5 (e.g., four major and
      two minor inclusion criteria)
      (<xref alt="Figure 3" rid="fig-heterogeneity">Figure 3</xref>).</p>
          <fig id="fig-heterogeneity">
            <caption>
              <p>Figure 3: Analysis of the Heterogeneity in Treatment
        Effects.</p>
            </caption>
            <graphic mimetype="image" mime-subtype="png" xlink:href="images/clipboard-2828008318.png"/>
          </fig>
        </sec>
      </sec>
      <sec id="exploratory-subgroup-analyses">
        <title>Exploratory Subgroup Analyses</title>
        <p>The beneficial effect of indomethacin on the primary outcome was
    also consistent across the other prespecified and post hoc secondary
    subgroups
    (<xref alt="Figure 4" rid="fig-exploratory-subgroup">Figure 4</xref>).
    In particular, indomethacin appeared to be protective regardless of
    whether patients had undergone pancreatic stenting or had a clinical
    suspicion of sphincter of Oddi dysfunction; indomethacin was also
    protective in all three subtypes of sphincter of Oddi dysfunction
    and in the two study sites enrolling the largest number of
    patients.</p>
        <fig id="fig-exploratory-subgroup">
          <caption>
            <p>Figure 4: Exploratory Subgroup Analyses</p>
          </caption>
          <graphic mimetype="image" mime-subtype="png" xlink:href="images/clipboard-1822931444.png"/>
        </fig>
      </sec>
      <sec id="adverse-events-1">
        <title>Adverse Events</title>
        <p>There were 13 adverse events that were potentially attributable
    to the study intervention
    (<xref alt="Figure 2" rid="fig-incidences-adverse-events">Figure 2</xref>).
    Clinically significant bleeding occurred in 11 patients (1.8%): 4 in
    the indomethacin group and 7 in the placebo group (P=0.72). None of
    the bleeding events resulted in transfusion of more than 2 units of
    packed red cells or required angiography or surgery for treatment.
    Two cases of acute renal failure occurred, both in the placebo
    group. There were no myocardial infarctions, strokes, or deaths at
    30-day follow-up.</p>
      </sec>
    </sec>
    <sec id="discussion">
      <title>Discussion</title>
      <p>Our findings showed that one dose of rectal indomethacin given
  immediately after ERCP significantly reduced the incidence of
  post-ERCP pancreatitis in patients at elevated risk for this
  complication. Moreover, we found that prophylactic indomethacin
  decreased the severity of post-ERCP pancreatitis and was associated
  with a shorter hospital stay. In this trial, the number of high-risk
  ERCP patients who would need to be treated to prevent one episode of
  pancreatitis was 13.</p>
      <p>The majority of patients in this study had a clinical suspicion of
  sphincter of Oddi dysfunction, and more than half had sphincter
  hypertension, as documented on manometry, which suggests that the
  results are particularly applicable to this challenging patient
  population. However, among patients who received indomethacin, there
  was a trend toward benefit with respect to rates of post-ERCP
  pancreatitis for those who did not have a clinical suspicion of
  sphincter of Oddi dysfunction (8.5% vs. 20.0%, P=0.11). Moreover, in a
  subgroup analysis, the relative treatment effect of indomethacin was
  consistent across the spectrum of patients’ risk of post-ERCP
  pancreatitis. Additional studies will be necessary to reproduce our
  results in different patient populations and to determine whether
  indomethacin is effective in low-risk patients, as suggested by our
  previous
  meta-analysis.(<xref alt="Andriulli et al. 2007" rid="ref-andriulli2007" ref-type="bibr">Andriulli
  et al. 2007</xref>)</p>
      <p>Although more than 80% of the patients in this clinical trial
  underwent pancreatic stenting on the basis of their elevated risk of
  post-ERCP pancreatitis, certain patients did not receive stents,
  either because the endoscopist did not deem it indicated (e.g.,
  difficult cannulation not requiring a precut sphincterotomy) or
  because placement was not technically feasible (failed pancreatic
  access). Among patients who received a pancreatic stent, indomethacin
  reduced the risk of post-ERCP pancreatitis from 16.1% to 9.7%
  (P=0.04). Indomethacin conferred similar benefit in patients who did
  not receive a pancreatic stent, reducing the risk of post-ERCP
  pancreatitis from 20.6% to 6.3% (P=0.049).</p>
      <p>Congruent with previous clinical trials evaluating NSAIDs in the
  prevention of post-ERCP pancreatitis, the risk of adverse events that
  were potentially attributable to indomethacin in this study was
  similar in the two study groups. Specifically, there was no
  significant between-group difference in the frequency or severity of
  bleeding events. This finding is consistent with previously published
  data suggesting that NSAIDs in standard doses do not increase the risk
  of bleeding after biliary
  sphincterotomy.(<xref alt="Martin L. Freeman et al. 1996" rid="ref-freeman1996" ref-type="bibr">Martin
  L. Freeman et al. 1996</xref>;
  <xref alt="Nelson and Freeman 1994" rid="ref-nelson1994major" ref-type="bibr">Nelson
  and Freeman 1994</xref>) Of note, patients with contraindications to
  NSAIDs, such as renal failure and active peptic-ulcer disease, were
  excluded from this study.</p>
      <p>The rate of post-ERCP pancreatitis in the placebo group (16.9%)
  exceeded that revealed by the internal audit of high-risk ERCP
  patients at participating institutions (16.9% vs. 10%). (These audit
  results had been used to calculate the sample size.) This difference
  may be due to the increased capture of complications that occurs in
  randomized, controlled trials. Nevertheless, the incidence of
  post-ERCP pancreatitis in the placebo group of this trial was similar
  to that in previous studies of NSAID pharmacoprevention in high-risk
  subjects, in which the mean rate of post-ERCP pancreatitis was
  18.8%.(<xref alt="Andriulli et al. 2007" rid="ref-andriulli2007" ref-type="bibr">Andriulli
  et al. 2007</xref>)</p>
      <p>In summary, prophylactic rectal indomethacin significantly reduced
  the incidence and severity of post-ERCP pancreatitis in patients at
  elevated risk for this complication, particularly in those with a
  clinical suspicion of sphincter of Oddi dysfunction.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title/>
      <ref id="ref-freeman2004">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freeman</surname>
              <given-names>Martin L</given-names>
            </name>
            <name>
              <surname>Guda</surname>
              <given-names>Nalini M</given-names>
            </name>
          </person-group>
          <article-title>Prevention of post-ERCP pancreatitis: a comprehensive review</article-title>
          <source>Gastrointestinal Endoscopy</source>
          <year iso-8601-date="2004-06">2004</year>
          <month>06</month>
          <volume>59</volume>
          <issue>7</issue>
          <uri>http://dx.doi.org/10.1016/S0016-5107(04)00353-0</uri>
          <pub-id pub-id-type="doi">10.1016/s0016-5107(04)00353-0</pub-id>
          <fpage>845</fpage>
          <lpage>864</lpage>
        </element-citation>
      </ref>
      <ref id="ref-freeman1996">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freeman</surname>
              <given-names>Martin L.</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>Douglas B.</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>Stuart</given-names>
            </name>
            <name>
              <surname>Haber</surname>
              <given-names>Gregory B.</given-names>
            </name>
            <name>
              <surname>Herman</surname>
              <given-names>Mary E.</given-names>
            </name>
            <name>
              <surname>Dorsher</surname>
              <given-names>Paul J.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>Joseph P.</given-names>
            </name>
            <name>
              <surname>Fennerty</surname>
              <given-names>M. Brian</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>Michael E.</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>Michael J.</given-names>
            </name>
            <name>
              <surname>Lande</surname>
              <given-names>Jeffrey D.</given-names>
            </name>
            <name>
              <surname>Pheley</surname>
              <given-names>Alfred M.</given-names>
            </name>
          </person-group>
          <article-title>Complications of Endoscopic Biliary Sphincterotomy</article-title>
          <source>New England Journal of Medicine</source>
          <year iso-8601-date="1996-09-26">1996</year>
          <month>09</month>
          <day>26</day>
          <volume>335</volume>
          <issue>13</issue>
          <uri>http://dx.doi.org/10.1056/NEJM199609263351301</uri>
          <pub-id pub-id-type="doi">10.1056/nejm199609263351301</pub-id>
          <fpage>909</fpage>
          <lpage>919</lpage>
        </element-citation>
      </ref>
      <ref id="ref-hcupnet2019utilization">
        <element-citation>
          <person-group person-group-type="author">
            <name>
              <surname>HCUPnet</surname>
              <given-names>Healthcare Cost</given-names>
            </name>
          </person-group>
          <article-title>Utilization project. Rockville, MD: Agency for healthcare research and quality, 2016</article-title>
          <year iso-8601-date="2019">2019</year>
        </element-citation>
      </ref>
      <ref id="ref-gross1993inflammatory">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gross</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Leser</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Heinisch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schölmerich</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory mediators and cytokines–new aspects of the pathophysiology and assessment of severity of acute pancreatitis?</article-title>
          <source>Hepato-gastroenterology</source>
          <year iso-8601-date="1993">1993</year>
          <volume>40</volume>
          <issue>6</issue>
          <fpage>522</fpage>
          <lpage>530</lpage>
        </element-citation>
      </ref>
      <ref id="ref-makela1997inhibition">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mäkelä</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kuusi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schröder</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro</article-title>
          <source>Scandinavian journal of clinical and laboratory investigation</source>
          <publisher-name>Taylor &amp; Francis</publisher-name>
          <year iso-8601-date="1997">1997</year>
          <volume>57</volume>
          <issue>5</issue>
          <fpage>401</fpage>
          <lpage>407</lpage>
        </element-citation>
      </ref>
      <ref id="ref-murray2003diclofenac">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>Bill</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>Ross</given-names>
            </name>
            <name>
              <surname>Imrie</surname>
              <given-names>Clem</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>Susan</given-names>
            </name>
            <name>
              <surname>O’suilleabhain</surname>
              <given-names>Criostoir</given-names>
            </name>
          </person-group>
          <article-title>Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography</article-title>
          <source>Gastroenterology</source>
          <publisher-name>Elsevier</publisher-name>
          <year iso-8601-date="2003">2003</year>
          <volume>124</volume>
          <issue>7</issue>
          <fpage>1786</fpage>
          <lpage>1791</lpage>
        </element-citation>
      </ref>
      <ref id="ref-sotoudehmanesh2007indomethacin">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sotoudehmanesh</surname>
              <given-names>Rasoul</given-names>
            </name>
            <name>
              <surname>Khatibian</surname>
              <given-names>Morteza</given-names>
            </name>
            <name>
              <surname>Kolahdoozan</surname>
              <given-names>Shadi</given-names>
            </name>
            <name>
              <surname>Ainechi</surname>
              <given-names>Sanaz</given-names>
            </name>
            <name>
              <surname>Malboosbaf</surname>
              <given-names>Ramin</given-names>
            </name>
            <name>
              <surname>Nouraie</surname>
              <given-names>Mehdi</given-names>
            </name>
          </person-group>
          <article-title>Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP</article-title>
          <source>Official journal of the American College of Gastroenterology| ACG</source>
          <publisher-name>LWW</publisher-name>
          <year iso-8601-date="2007">2007</year>
          <volume>102</volume>
          <issue>5</issue>
          <fpage>978</fpage>
          <lpage>983</lpage>
        </element-citation>
      </ref>
      <ref id="ref-khoshbaten2008role">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khoshbaten</surname>
              <given-names>Manouchehr</given-names>
            </name>
            <name>
              <surname>Khorram</surname>
              <given-names>Homayoun</given-names>
            </name>
            <name>
              <surname>Madad</surname>
              <given-names>Leili</given-names>
            </name>
            <name>
              <surname>Ehsani Ardakani</surname>
              <given-names>Mohammad Javad</given-names>
            </name>
            <name>
              <surname>Farzin</surname>
              <given-names>Haleh</given-names>
            </name>
            <name>
              <surname>Zali</surname>
              <given-names>Mohammmad Reza</given-names>
            </name>
          </person-group>
          <article-title>Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis</article-title>
          <source>Journal of gastroenterology and hepatology</source>
          <publisher-name>Wiley Online Library</publisher-name>
          <year iso-8601-date="2008">2008</year>
          <volume>23</volume>
          <issue>7pt2</issue>
          <fpage>e11</fpage>
          <lpage>e16</lpage>
        </element-citation>
      </ref>
      <ref id="ref-je2007effect">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>JE</surname>
              <given-names>Garcı́a Correa</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes</article-title>
          <source>Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva</source>
          <year iso-8601-date="2007">2007</year>
          <volume>99</volume>
          <issue>6</issue>
          <fpage>330</fpage>
          <lpage>336</lpage>
        </element-citation>
      </ref>
      <ref id="ref-elmunzer2008">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elmunzer</surname>
              <given-names>B J</given-names>
            </name>
            <name>
              <surname>Waljee</surname>
              <given-names>A K</given-names>
            </name>
            <name>
              <surname>Elta</surname>
              <given-names>G H</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>J R</given-names>
            </name>
            <name>
              <surname>Fehmi</surname>
              <given-names>S M A</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>P D R</given-names>
            </name>
          </person-group>
          <article-title>A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis</article-title>
          <source>Gut</source>
          <year iso-8601-date="2008-03-28">2008</year>
          <month>03</month>
          <day>28</day>
          <volume>57</volume>
          <issue>9</issue>
          <uri>http://dx.doi.org/10.1136/gut.2007.140756</uri>
          <pub-id pub-id-type="doi">10.1136/gut.2007.140756</pub-id>
          <fpage>1262</fpage>
          <lpage>1267</lpage>
        </element-citation>
      </ref>
      <ref id="ref-tarnasky1998">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tarnasky</surname>
              <given-names>Paul R.</given-names>
            </name>
            <name>
              <surname>Palesch</surname>
              <given-names>Yuko Y.</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>John T.</given-names>
            </name>
            <name>
              <surname>Mauldin</surname>
              <given-names>Patrick D.</given-names>
            </name>
            <name>
              <surname>Cotton</surname>
              <given-names>Peter B.</given-names>
            </name>
            <name>
              <surname>Hawes</surname>
              <given-names>Robert H.</given-names>
            </name>
          </person-group>
          <article-title>Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction</article-title>
          <source>Gastroenterology</source>
          <year iso-8601-date="1998-12">1998</year>
          <month>12</month>
          <volume>115</volume>
          <issue>6</issue>
          <uri>http://dx.doi.org/10.1016/S0016-5085(98)70031-9</uri>
          <pub-id pub-id-type="doi">10.1016/s0016-5085(98)70031-9</pub-id>
          <fpage>1518</fpage>
          <lpage>1524</lpage>
        </element-citation>
      </ref>
      <ref id="ref-fazel2003">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fazel</surname>
              <given-names>Ali</given-names>
            </name>
            <name>
              <surname>Quadri</surname>
              <given-names>Affan</given-names>
            </name>
            <name>
              <surname>Catalano</surname>
              <given-names>Marc F.</given-names>
            </name>
            <name>
              <surname>Meyerson</surname>
              <given-names>Scott M.</given-names>
            </name>
            <name>
              <surname>Geenen</surname>
              <given-names>Joseph E.</given-names>
            </name>
          </person-group>
          <article-title>Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study</article-title>
          <source>Gastrointestinal Endoscopy</source>
          <year iso-8601-date="2003-03">2003</year>
          <month>03</month>
          <volume>57</volume>
          <issue>3</issue>
          <uri>http://dx.doi.org/10.1067/mge.2003.124</uri>
          <pub-id pub-id-type="doi">10.1067/mge.2003.124</pub-id>
          <fpage>291</fpage>
          <lpage>294</lpage>
        </element-citation>
      </ref>
      <ref id="ref-singh2004">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>Pankaj</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>Ananya</given-names>
            </name>
            <name>
              <surname>Isenberg</surname>
              <given-names>Gerard</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>Richard C. K.</given-names>
            </name>
            <name>
              <surname>Sivak</surname>
              <given-names>Michael V.</given-names>
            </name>
            <name>
              <surname>Agrawal</surname>
              <given-names>Deepak</given-names>
            </name>
            <name>
              <surname>Chak</surname>
              <given-names>Amitabh</given-names>
            </name>
          </person-group>
          <article-title>Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials</article-title>
          <source>Gastrointestinal Endoscopy</source>
          <year iso-8601-date="2004-10">2004</year>
          <month>10</month>
          <volume>60</volume>
          <issue>4</issue>
          <uri>http://dx.doi.org/10.1016/S0016-5107(04)02013-9</uri>
          <pub-id pub-id-type="doi">10.1016/s0016-5107(04)02013-9</pub-id>
          <fpage>544</fpage>
          <lpage>550</lpage>
        </element-citation>
      </ref>
      <ref id="ref-dumonceau2010">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dumonceau</surname>
              <given-names>Jean-Marc</given-names>
            </name>
            <name>
              <surname>Rigaux</surname>
              <given-names>Johanne</given-names>
            </name>
            <name>
              <surname>Kahaleh</surname>
              <given-names>Michel</given-names>
            </name>
            <name>
              <surname>Gomez</surname>
              <given-names>Carlos Macias</given-names>
            </name>
            <name>
              <surname>Vandermeeren</surname>
              <given-names>Alain</given-names>
            </name>
            <name>
              <surname>Devière</surname>
              <given-names>Jacques</given-names>
            </name>
          </person-group>
          <article-title>Prophylaxis of post-ERCP pancreatitis: a practice survey</article-title>
          <source>Gastrointestinal Endoscopy</source>
          <year iso-8601-date="2010-05">2010</year>
          <month>05</month>
          <volume>71</volume>
          <issue>6</issue>
          <uri>http://dx.doi.org/10.1016/j.gie.2009.10.055</uri>
          <pub-id pub-id-type="doi">10.1016/j.gie.2009.10.055</pub-id>
          <fpage>934</fpage>
          <lpage>939.e2</lpage>
        </element-citation>
      </ref>
      <ref id="ref-andriulli2000">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andriulli</surname>
              <given-names>Angelo</given-names>
            </name>
            <name>
              <surname>Leandro</surname>
              <given-names>Gioacchino</given-names>
            </name>
            <name>
              <surname>Niro</surname>
              <given-names>Grazia</given-names>
            </name>
            <name>
              <surname>Mangia</surname>
              <given-names>Alessandra</given-names>
            </name>
            <name>
              <surname>Festa</surname>
              <given-names>Virginia</given-names>
            </name>
            <name>
              <surname>Gambassi</surname>
              <given-names>Giovanni</given-names>
            </name>
            <name>
              <surname>Villani</surname>
              <given-names>Maria Rosaria</given-names>
            </name>
            <name>
              <surname>Facciorusso</surname>
              <given-names>Domenico</given-names>
            </name>
            <name>
              <surname>Conoscitore</surname>
              <given-names>Pasquale</given-names>
            </name>
            <name>
              <surname>Spirito</surname>
              <given-names>Fulvio</given-names>
            </name>
            <name>
              <surname>De Maio</surname>
              <given-names>Giovanni</given-names>
            </name>
          </person-group>
          <article-title>Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis</article-title>
          <source>Gastrointestinal Endoscopy</source>
          <year iso-8601-date="2000-01">2000</year>
          <month>01</month>
          <volume>51</volume>
          <issue>1</issue>
          <uri>http://dx.doi.org/10.1016/S0016-5107(00)70377-4</uri>
          <pub-id pub-id-type="doi">10.1016/s0016-5107(00)70377-4</pub-id>
          <fpage>1</fpage>
          <lpage>7</lpage>
        </element-citation>
      </ref>
      <ref id="ref-andriulli2007">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andriulli</surname>
              <given-names>Angelo</given-names>
            </name>
            <name>
              <surname>Leandro</surname>
              <given-names>Gioacchino</given-names>
            </name>
            <name>
              <surname>Federici</surname>
              <given-names>Telemaco</given-names>
            </name>
            <name>
              <surname>Ippolito</surname>
              <given-names>Antonio</given-names>
            </name>
            <name>
              <surname>Forlano</surname>
              <given-names>Rosario</given-names>
            </name>
            <name>
              <surname>Iacobellis</surname>
              <given-names>Angelo</given-names>
            </name>
            <name>
              <surname>Annese</surname>
              <given-names>Vito</given-names>
            </name>
          </person-group>
          <article-title>Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis</article-title>
          <source>Gastrointestinal Endoscopy</source>
          <year iso-8601-date="2007-04">2007</year>
          <month>04</month>
          <volume>65</volume>
          <issue>4</issue>
          <uri>http://dx.doi.org/10.1016/j.gie.2006.10.030</uri>
          <pub-id pub-id-type="doi">10.1016/j.gie.2006.10.030</pub-id>
          <fpage>624</fpage>
          <lpage>632</lpage>
        </element-citation>
      </ref>
      <ref id="ref-freeman2007">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freeman</surname>
              <given-names>Martin L.</given-names>
            </name>
          </person-group>
          <article-title>Pancreatic Stents for Prevention of PostEndoscopic Retrograde Cholangiopancreatography Pancreatitis</article-title>
          <source>Clinical Gastroenterology and Hepatology</source>
          <year iso-8601-date="2007-11">2007</year>
          <month>11</month>
          <volume>5</volume>
          <issue>11</issue>
          <uri>http://dx.doi.org/10.1016/j.cgh.2007.09.007</uri>
          <pub-id pub-id-type="doi">10.1016/j.cgh.2007.09.007</pub-id>
          <fpage>1354</fpage>
          <lpage>1365</lpage>
        </element-citation>
      </ref>
      <ref id="ref-vandermarel2004">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marel</surname>
              <given-names>Caroline D. van der</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>Brian J.</given-names>
            </name>
            <name>
              <surname>Rømsing</surname>
              <given-names>Janne</given-names>
            </name>
            <name>
              <surname>Jacqz-Aigrain</surname>
              <given-names>Evelyne</given-names>
            </name>
            <name>
              <surname>Tibboel</surname>
              <given-names>Dick</given-names>
            </name>
          </person-group>
          <article-title>Diclofenac and metabolite pharmacokinetics in children</article-title>
          <source>Pediatric Anesthesia</source>
          <year iso-8601-date="2004-05-20">2004</year>
          <month>05</month>
          <day>20</day>
          <volume>14</volume>
          <issue>6</issue>
          <uri>http://dx.doi.org/10.1111/j.1460-9592.2004.01232.x</uri>
          <pub-id pub-id-type="doi">10.1111/j.1460-9592.2004.01232.x</pub-id>
          <fpage>443</fpage>
          <lpage>451</lpage>
        </element-citation>
      </ref>
      <ref id="ref-cotton1991">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cotton</surname>
              <given-names>P. B.</given-names>
            </name>
            <name>
              <surname>Lehman</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Vennes</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Geenen</surname>
              <given-names>J. E.</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>R. C. G.</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>W. C.</given-names>
            </name>
            <name>
              <surname>Liguory</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Nickl</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Endoscopic sphincterotomy complications and their management: an attempt at consensus</article-title>
          <source>Gastrointestinal Endoscopy</source>
          <year iso-8601-date="1991-05">1991</year>
          <month>05</month>
          <volume>37</volume>
          <issue>3</issue>
          <uri>http://dx.doi.org/10.1016/S0016-5107(91)70740-2</uri>
          <pub-id pub-id-type="doi">10.1016/s0016-5107(91)70740-2</pub-id>
          <fpage>383</fpage>
          <lpage>393</lpage>
        </element-citation>
      </ref>
      <ref id="ref-mallery2003">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mallery</surname>
              <given-names>J.Shawn</given-names>
            </name>
            <name>
              <surname>Baron</surname>
              <given-names>Todd H.</given-names>
            </name>
            <name>
              <surname>Dominitz</surname>
              <given-names>Jason A.</given-names>
            </name>
            <name>
              <surname>Goldstein</surname>
              <given-names>Jay L.</given-names>
            </name>
            <name>
              <surname>Hirota</surname>
              <given-names>William K.</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>Brian C.</given-names>
            </name>
            <name>
              <surname>Leighton</surname>
              <given-names>Jonathan A.</given-names>
            </name>
            <name>
              <surname>Raddawi</surname>
              <given-names>Hareth M.</given-names>
            </name>
            <name>
              <surname>Varg</surname>
              <given-names>John J.</given-names>
            </name>
            <name>
              <surname>Waring</surname>
              <given-names>J.Patrick</given-names>
            </name>
            <name>
              <surname>Fanelli</surname>
              <given-names>Robert D.</given-names>
            </name>
            <name>
              <surname>Wheeler-Harbough</surname>
              <given-names>Jo</given-names>
            </name>
            <name>
              <surname>Eisen</surname>
              <given-names>Glenn M.</given-names>
            </name>
            <name>
              <surname>Faigel</surname>
              <given-names>Douglas O.</given-names>
            </name>
          </person-group>
          <article-title>Complications of ERCP</article-title>
          <source>Gastrointestinal Endoscopy</source>
          <year iso-8601-date="2003-05">2003</year>
          <month>05</month>
          <volume>57</volume>
          <issue>6</issue>
          <uri>http://dx.doi.org/10.1053/ge.2003.v57.amge030576633</uri>
          <pub-id pub-id-type="doi">10.1053/ge.2003.v57.amge030576633</pub-id>
          <fpage>633</fpage>
          <lpage>638</lpage>
        </element-citation>
      </ref>
      <ref id="ref-kent2010">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kent</surname>
              <given-names>David M</given-names>
            </name>
            <name>
              <surname>Rothwell</surname>
              <given-names>Peter M</given-names>
            </name>
            <name>
              <surname>Ioannidis</surname>
              <given-names>John PA</given-names>
            </name>
            <name>
              <surname>Altman</surname>
              <given-names>Doug G</given-names>
            </name>
            <name>
              <surname>Hayward</surname>
              <given-names>Rodney A</given-names>
            </name>
          </person-group>
          <article-title>Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal</article-title>
          <source>Trials</source>
          <year iso-8601-date="2010-08-12">2010</year>
          <month>08</month>
          <day>12</day>
          <volume>11</volume>
          <issue>1</issue>
          <uri>http://dx.doi.org/10.1186/1745-6215-11-85</uri>
          <pub-id pub-id-type="doi">10.1186/1745-6215-11-85</pub-id>
        </element-citation>
      </ref>
      <ref id="ref-nelson1994major">
        <element-citation publication-type="article-journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nelson</surname>
              <given-names>Douglas B</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>Martin L</given-names>
            </name>
          </person-group>
          <article-title>Major hemorrhage from endoscopic sphincterotomy: Risk factor analysis</article-title>
          <source>Journal of clinical gastroenterology</source>
          <publisher-name>LWW</publisher-name>
          <year iso-8601-date="1994">1994</year>
          <volume>19</volume>
          <issue>4</issue>
          <fpage>283</fpage>
          <lpage>287</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="notebook" id="nb-12-nb-article">
    <front-stub>
      <title-group>
        <article-title>A Randomized Trial of Rectal Indomethacin to Prevent
Post-ERCP Pancreatitis</article-title>
        <subtitle>Reproduction</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>B. Joseph Elmunzer</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>B. Joseph Elmunzer, M.D.</string-name>
          <role vocab="https://credit.niso.org" vocab-term="writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">writing</role>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
          <xref ref-type="corresp" rid="cor-1-nb-article">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>James M. Scheiman</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>James M. Scheiman, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Glen A. Lehman</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Glen A. Lehman, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2-nb-article">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Amitabh Chak</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Amitabh Chak, M.D.</string-name>
          <xref ref-type="aff" rid="aff-3-nb-article">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Patrick Mosler</surname>
            <given-names>Ph.D.</given-names>
          </name>
          <string-name>Patrick Mosler, M.D., Ph.D.</string-name>
          <xref ref-type="aff" rid="aff-4-nb-article">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-1602-4341</contrib-id>
          <name>
            <surname>Peter D. R. Higgins</surname>
            <given-names>Ph.D.</given-names>
          </name>
          <string-name>Peter D.R. Higgins, M.D., Ph.D.</string-name>
          <email>phiggins@umich.edu</email>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodney A. Hayward</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Rodney A. Hayward, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joseph Romagnuolo</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Joseph Romagnuolo, M.D.</string-name>
          <xref ref-type="aff" rid="aff-5-nb-article">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grace H. Elta</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Grace H. Elta, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stuart Sherman</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Stuart Sherman, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2-nb-article">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Akbar K. Waljee</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Akbar K. Waljee, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aparna Repaka</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Aparna Repaka, M.D.</string-name>
          <xref ref-type="aff" rid="aff-3-nb-article">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matthew R. Atkinson</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Matthew R. Atkinson, M.D.</string-name>
          <xref ref-type="aff" rid="aff-3-nb-article">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gregory A. Cote</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Gregory A. Cote, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2-nb-article">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Richard S. Kwon</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Richard S. Kwon, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee McHenry</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Lee McHenry, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2-nb-article">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cyrus R. Piraka</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Cyrus R. Piraka, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Erik J. Wamsteker</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Erik J. Wamsteker, M.D.</string-name>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>James L. Watkins</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>James L. Watkins, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2-nb-article">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sheryl J. Korsnes</surname>
            <given-names>M. A.</given-names>
          </name>
          <string-name>Sheryl J. Korsnes, M.A.</string-name>
          <xref ref-type="aff" rid="aff-1-nb-article">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suzette E. Schmidt</surname>
            <given-names>C. C. R. P.</given-names>
          </name>
          <string-name>Suzette E. Schmidt, B.S.N., C.C.R.P.</string-name>
          <xref ref-type="aff" rid="aff-2-nb-article">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sarah M. Turner</surname>
            <given-names>B. S.</given-names>
          </name>
          <string-name>Sarah M. Turner, B.S.</string-name>
          <xref ref-type="aff" rid="aff-4-nb-article">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sylvia Nicholson</surname>
            <given-names>C. C. R. C.</given-names>
          </name>
          <string-name>Sylvia Nicholson, C.C.R.C.</string-name>
          <xref ref-type="aff" rid="aff-4-nb-article">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Evan L. Fogel</surname>
            <given-names>M. D.</given-names>
          </name>
          <string-name>Evan L. Fogel, M.D.</string-name>
          <xref ref-type="aff" rid="aff-2-nb-article">b</xref>
        </contrib>
      </contrib-group>
      <aff id="aff-1-nb-article">
        <institution-wrap>
          <institution>University of Michigan Medical Center</institution>
        </institution-wrap>
      </aff>
      <aff id="aff-2-nb-article">
        <institution-wrap>
          <institution>Indiana University Medical Center</institution>
        </institution-wrap>
      </aff>
      <aff id="aff-3-nb-article">
        <institution-wrap>
          <institution>University Hospitals Case Medical Center</institution>
        </institution-wrap>
      </aff>
      <aff id="aff-4-nb-article">
        <institution-wrap>
          <institution>University of Kentucky Medical Center</institution>
        </institution-wrap>
      </aff>
      <aff id="aff-5-nb-article">
        <institution-wrap>
          <institution>Medical University of South Carolina</institution>
        </institution-wrap>
      </aff>
      <author-notes>
        <corresp id="cor-1-nb-article"/>
      </author-notes>
      <abstract>
        <p><bold>BACKGROUND</bold> Preliminary research suggests that rectally
administered nonsteroidal antiinflammatory drugs may reduce the
incidence of pancreatitis after endoscopic retrograde
cholangiopancreatography (ERCP).</p>
        <p><bold>METHODS</bold> In this multicenter, randomized,
placebo-controlled, double-blind clinical trial, we assigned patients at
elevated risk for post-ERCP pancreatitis to receive a single dose of
rectal indomethacin or placebo immediately after ERCP. Patients were
determined to be at high risk on the basis of validated patient- and
procedure-related risk factors. The primary outcome was post-ERCP
pancreatitis, which was defined as new upper abdominal pain, an
elevation in pancreatic enzymes to at least three times the upper limit
of the normal range 24 hours after the procedure, and hospitalization
for at least 2 nights.</p>
        <p><bold>RESULTS</bold> A total of 602 patients were enrolled and
completed follow-up. The majority of patients (82%) had a clinical
suspicion of sphincter of Oddi dysfunction. Post-ERCP pancreatitis
developed in 27 of 295 patients (9.2%) in the indomethacin group and in
52 of 307 patients (16.9%) in the placebo group (P=0.005).
Moderate-to-severe pancreatitis developed in 13 patients (4.4%) in the
indomethacin group and in 27 patients (8.8%) in the placebo group
(P=0.03).</p>
        <p><bold>CONCLUSIONS</bold> Among patients at high risk for post-ERCP
pancreatitis, rectal indomethacin significantly reduced the incidence of
the condition. (Funded by the National Institutes of Health;
ClinicalTrials.gov number, NCT00820612. opens in new tab.)</p>
      </abstract>
    </front-stub>
    <body>
      <boxed-text>
        <disp-quote>
          <p>
            <bold>Important</bold>
          </p>
          <p>This is a Quarto reproduction of a paper published in the New
    England Journal of Medicine in 2012, which you can find at
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/full/10.1056/NEJMoa1111103">https://www.nejm.org/doi/full/10.1056/NEJMoa1111103</ext-link>.
    Some of the reproduction code was provided by Peter Higgins.</p>
        </disp-quote>
      </boxed-text>
      <sec id="nb-code-cell-1-nb-article" specific-use="notebook-code">
        <code language="r script">library(tidyverse)</code>
        <code language="r script">library(medicaldata)
library(consort)
library(gtsummary)</code>
        <sec id="nb-code-cell-1-output-0-nb-article" specific-use="notebook-output">
          <preformat>── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
✔ dplyr     1.1.4     ✔ readr     2.1.4
✔ forcats   1.0.0     ✔ stringr   1.5.1
✔ ggplot2   3.5.0     ✔ tibble    3.2.1
✔ lubridate 1.9.3     ✔ tidyr     1.3.1
✔ purrr     1.0.2     
── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
✖ dplyr::filter() masks stats::filter()
✖ dplyr::lag()    masks stats::lag()
ℹ Use the conflicted package (&lt;http://conflicted.r-lib.org/&gt;) to force all conflicts to become errors</preformat>
        </sec>
      </sec>
      <p>Acute pancreatitis is the most common major complication of
endoscopic retrograde cholangiopancreatography
(ERCP),(<xref alt="Martin L. Freeman and Guda 2004" rid="ref-freeman2004-nb-article" ref-type="bibr">Martin
L. Freeman and Guda 2004</xref>) accounting for substantial morbidity,
occasional death, and estimated health care expenditures of
approximately $150 million annually in the United
States.(<xref alt="Martin L. Freeman et al. 1996" rid="ref-freeman1996-nb-article" ref-type="bibr">Martin
L. Freeman et al. 1996</xref>;
<xref alt="HCUPnet 2019" rid="ref-hcupnet2019utilization-nb-article" ref-type="bibr">HCUPnet
2019</xref>) Given the magnitude of this problem, more than 35
pharmacologic agents have been studied for the prophylaxis of post-ERCP
pancreatitis, and many prospective clinical trials addressing
chemoprevention have been conducted. To date, however, no medication has
proved to be consistently effective in preventing post-ERCP pancreatitis
on the basis of data from high-quality clinical trials, and no
pharmacologic prophylaxis for post-ERCP pancreatitis is in widespread
clinical use.</p>
      <p>Nonsteroidal antiinflammatory drugs (NSAIDs) are potent inhibitors of
phospholipase A2, cyclooxygenase, and neutrophil–endothelial
interactions, all believed to play an important role in the pathogenesis
of acute
pancreatitis.(<xref alt="Gross et al. 1993" rid="ref-gross1993inflammatory-nb-article" ref-type="bibr">Gross
et al. 1993</xref>;
<xref alt="Mäkelä, Kuusi, and Schröder 1997" rid="ref-makela1997inhibition-nb-article" ref-type="bibr">Mäkelä,
Kuusi, and Schröder 1997</xref>) NSAIDs are inexpensive and easily
administered and have a favorable risk profile when given as a single
dose, making them an attractive option in the prevention of post-ERCP
pancreatitis. Preliminary studies evaluating the protective effects of
single-dose rectal indomethacin or diclofenac in post-ERCP pancreatitis
have been
conducted,(<xref alt="Murray et al. 2003" rid="ref-murray2003diclofenac-nb-article" ref-type="bibr">Murray
et al. 2003</xref>;
<xref alt="Sotoudehmanesh et al. 2007" rid="ref-sotoudehmanesh2007indomethacin-nb-article" ref-type="bibr">Sotoudehmanesh
et al. 2007</xref>;
<xref alt="Khoshbaten et al. 2008" rid="ref-khoshbaten2008role-nb-article" ref-type="bibr">Khoshbaten
et al. 2008</xref>;
<xref alt="JE et al. 2007" rid="ref-je2007effect-nb-article" ref-type="bibr">JE et
al. 2007</xref>) and a meta-analysis suggests
benefit.(<xref alt="Elmunzer et al. 2008" rid="ref-elmunzer2008-nb-article" ref-type="bibr">Elmunzer
et al. 2008</xref>)</p>
      <p>Despite these data, rectal NSAIDs are seldom used in clinical
practice because there is no conclusive evidence from randomized,
controlled
trials(<xref alt="Dumonceau et al. 2010" rid="ref-dumonceau2010-nb-article" ref-type="bibr">Dumonceau
et al. 2010</xref>) and because previous positive meta-analyses of other
agents for the prevention of post-ERCP pancreatitis have been disproved
by further
investigation.(<xref alt="Andriulli et al. 2000" rid="ref-andriulli2000-nb-article" ref-type="bibr">Andriulli
et al. 2000</xref>,
<xref alt="2007" rid="ref-andriulli2007-nb-article" ref-type="bibr">2007</xref>)
Moreover, it remains unclear whether NSAIDs provide incremental benefit
over temporary pancreatic stents, the only proven prophylactic
intervention for post-ERCP
pancreatitis.(<xref alt="Tarnasky et al. 1998" rid="ref-tarnasky1998-nb-article" ref-type="bibr">Tarnasky
et al. 1998</xref>;
<xref alt="Fazel et al. 2003" rid="ref-fazel2003-nb-article" ref-type="bibr">Fazel
et al. 2003</xref>;
<xref alt="Singh et al. 2004" rid="ref-singh2004-nb-article" ref-type="bibr">Singh
et al. 2004</xref>) Therefore, we conducted a multicenter, randomized,
controlled clinical trial to evaluate the efficacy of prophylactic
rectal indomethacin for the prevention of post-ERCP pancreatitis in
high-risk patients.</p>
      <sec id="methods-nb-article">
        <title>Methods</title>
        <sec id="study-design-nb-article">
          <title>Study design</title>
          <p>We enrolled patients at four university-affiliated medical
    centers in the United States after approval from the human studies
    review committee at each institution. An independent data and safety
    monitoring board provided regulatory oversight by reviewing blinded
    subject data quarterly and conducting the a priori scheduled interim
    analysis. The complete study
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_protocol.pdf"><bold>protocol</bold></ext-link>
    is available with the full text of this article at NEJM.org.</p>
        </sec>
        <sec id="patients-nb-article">
          <title>Patients</title>
          <p>The inclusion criteria selected patients with an elevated
    baseline risk of post-ERCP pancreatitis on the basis of
    prospectively validated patient- and procedure-related independent
    risk
    factors.(<xref alt="Martin L. Freeman 2007" rid="ref-freeman2007-nb-article" ref-type="bibr">Martin
    L. Freeman 2007</xref>) Patients were eligible if they met one or
    more of the following major criteria: clinical suspicion of
    sphincter of Oddi dysfunction (as defined in the
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_appendix.pdf"><bold>Supplementary
    Appendix</bold></ext-link>, available at NEJM.org), a history of
    post-ERCP pancreatitis, pancreatic sphincterotomy, precut
    sphincterotomy (a procedure performed to facilitate biliary access
    when standard cannulation techniques are unsuccessful), more than
    eight cannulation attempts (as determined by the endoscopist),
    pneumatic dilatation of an intact biliary sphincter, or
    ampullectomy. Patients were also eligible for inclusion if they met
    two or more of the following minor criteria: an age of less than 50
    years and female sex, a history of recurrent pancreatitis
    (<inline-formula><alternatives><tex-math><![CDATA[\ge]]></tex-math><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:mo>≥</mml:mo></mml:math></alternatives></inline-formula>
    2 episodes), three or more injections of contrast agent into the
    pancreatic duct with at least one injection to the tail of the
    pancreas, excessive injection of contrast agent into the pancreatic
    duct resulting in opacification of pancreatic acini, or the
    acquisition of a cytologic specimen from the pancreatic duct with
    the use of a brush.</p>
          <p>The exclusion criteria are listed in the
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_appendix.pdf"><bold>Supplementary
    Appendix</bold></ext-link> and were intended to exclude patients in
    whom ERCP was unsuitable and those who had active pancreatitis, had
    a contraindication to the use of NSAIDs (e.g., creatinine level,
    &gt;1.4 mg per deciliter [124 <inline-formula><alternatives><tex-math><![CDATA[\mu]]></tex-math><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>mol
    per liter] or active peptic ulcer disease), were already taking
    NSAIDs (other than cardioprotective aspirin), or had an anticipated
    low risk of post-ERCP pancreatitis (e.g., those with chronic
    calcific pancreatitis or a pancreatic-head mass or those undergoing
    routine biliary-stent exchange).</p>
          <p>Eligible patients who provided written informed consent underwent
    randomization at the conclusion of the ERCP procedure, because
    patients without risk factors could be included in the study on the
    basis of procedure-related factors alone.</p>
        </sec>
        <sec id="intervention-nb-article">
          <title>Intervention</title>
          <p>All procedure-related interventions were dictated by the
    performing endoscopist. Immediately after the procedure, if the
    endoscopist and research coordinator determined that inclusion
    criteria had been met, patients were randomly assigned to receive
    either two 50-mg indomethacin suppositories or two
    identical-appearing placebo suppositories. The randomization
    schedule, which was stratified according to study center, was
    generated centrally at the University of Michigan.</p>
          <p>The suppositories were administered immediately after ERCP while
    the patient was still in the procedure room. The rectal route was
    selected on the basis of available pilot data suggesting that only
    rectal NSAIDs are effective in preventing post-ERCP pancreatitis,
    perhaps owing to more rapid and complete bioavailability than with
    oral
    administration.(<xref alt="Elmunzer et al. 2008" rid="ref-elmunzer2008-nb-article" ref-type="bibr">Elmunzer
    et al. 2008</xref>;
    <xref alt="Marel et al. 2004" rid="ref-vandermarel2004-nb-article" ref-type="bibr">Marel
    et al. 2004</xref>) The indomethacin suppositories were purchased
    from two vendors: G&amp;W Laboratories and Custom Med Apothecary.
    Formal potency testing confirmed that the vendors provided
    indomethacin suppositories that were pharmacodynamically equivalent
    (Analytic Research Laboratories).</p>
        </sec>
        <sec id="outcomes-nb-article">
          <title>Outcomes</title>
          <p>The primary outcome of the study was the development of post-ERCP
    pancreatitis, which was defined according to consensus
    criteria(<xref alt="Cotton et al. 1991" rid="ref-cotton1991-nb-article" ref-type="bibr">Cotton
    et al. 1991</xref>) (details are provided in the
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_appendix.pdf"><bold>Supplementary
    Appendix</bold></ext-link>). Briefly, post-ERCP pancreatitis was
    diagnosed if there was a new onset of pain in the upper abdomen, an
    elevation in pancreatic enzymes of at least three times the upper
    limit of the normal range 24 hours after the procedure, and
    hospitalization for at least 2 nights. The secondary outcome was the
    development of moderate or severe post-ERCP pancreatitis (see the
    <ext-link ext-link-type="uri" xlink:href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa1111103/suppl_file/nejmoa1111103_appendix.pdf"><bold>Supplementary
    Appendix</bold></ext-link>). Data regarding the length of hospital
    stay for patients with post-ERCP pancreatitis were collected
    prospectively, but the duration of hospitalization was not a
    prespecified outcome measure and was therefore analyzed post
    hoc.</p>
          <p>Patients were observed in the recovery area for at least 90
    minutes after the procedure. Patients in whom abdominal pain
    developed during this observation period were admitted to the
    hospital (or for current inpatients, kept in the hospital).
    Decisions regarding evaluation of complications after the procedure
    and in-hospital care were left to the discretion of the endoscopist
    and clinical-service staff members, who were unaware of study-group
    assignments. Serum amylase and lipase were measured in hospitalized
    patients at least once 24 hours after the procedure and subsequently
    at clinical discretion.</p>
          <p>Patients who were discharged after an uneventful ERCP were
    contacted by telephone within 5 days to capture delayed occurrence
    of the primary end point. Patients were again contacted at 30 days
    to assess for delayed adverse events and to determine the severity
    of post-ERCP pancreatitis, which was defined in part by the length
    of hospitalization for pancreatitis. The original study protocol
    stated that the primary end point would be assessed within 48 hours
    after the procedure. Although post-ERCP pancreatitis generally
    occurs within this period, we contacted patients up to 5 days after
    ERCP to ensure capture of delayed cases of the primary end
    point.</p>
          <p>Patient demographics, risk factors, ERCP procedural elements, and
    follow-up data were recorded on standardized data-collection forms
    by an investigator or coordinator who was unaware of study-group
    assignments. All data were subsequently entered into a Web-based
    database, Velos eResearch, and managed by an independent
    data-management service.</p>
        </sec>
        <sec id="adverse-events-nb-article">
          <title>Adverse events</title>
          <p>Adverse events were defined as reported
    previously.(<xref alt="Cotton et al. 1991" rid="ref-cotton1991-nb-article" ref-type="bibr">Cotton
    et al. 1991</xref>;
    <xref alt="Mallery et al. 2003" rid="ref-mallery2003-nb-article" ref-type="bibr">Mallery
    et al. 2003</xref>) Any cases of post-ERCP pancreatitis, other
    complications of the procedure, and adverse events that were
    potentially attributable to the study drug were reported to the
    local institutional review board and the data and safety monitoring
    board. These reportable adverse events were gastrointestinal
    bleeding, perforation, infection, renal failure, allergic reaction,
    myocardial infarction, cerebrovascular accident, and death.</p>
        </sec>
        <sec id="statistical-analysis-nb-article">
          <title>Statistical analysis</title>
          <p>The prophylactic placement of pancreatic stents has been shown to
    reduce the rate of post-ERCP pancreatitis to 5 to 10% among
    high-risk
    patients.(<xref alt="Tarnasky et al. 1998" rid="ref-tarnasky1998-nb-article" ref-type="bibr">Tarnasky
    et al. 1998</xref>;
    <xref alt="Fazel et al. 2003" rid="ref-fazel2003-nb-article" ref-type="bibr">Fazel
    et al. 2003</xref>;
    <xref alt="Singh et al. 2004" rid="ref-singh2004-nb-article" ref-type="bibr">Singh
    et al. 2004</xref>) An internal audit of high-risk ERCPs at
    participating institutions revealed a post-ERCP rate of pancreatitis
    of approximately 10%, despite routine prophylactic stent placement
    in appropriate patients. We estimated that 948 patients (474 per
    study group) would provide a power of at least 80% to detect a 50%
    reduction in the incidence of post-ERCP pancreatitis, from 10% in
    the placebo group to 5% in the indomethacin group, on the basis of
    Fisher’s exact test, with a two-sided significance level of
    0.05.</p>
          <p>For the analysis of the primary end point, we used a two-tailed
    Fisher’s exact test to analyze the difference in the proportion of
    patients with post-ERCP pancreatitis in the indomethacin group and
    the placebo group, with a final two-sided P value of less than 0.041
    indicating statistical significance. This P value reflects the
    partial spending of degrees of freedom of statistical testing that
    resulted from conducting two interim analyses on the basis of the
    O’Brien–Fleming approach and the Lan–DeMets alpha spending function.
    Results for the primary end point were reported in terms of absolute
    and relative risk reduction. The secondary end point, the proportion
    of patients with moderate or severe post-ERCP pancreatitis in each
    study group, was similarly calculated, with a P value of less than
    0.05 indicating statistical significance. Hospital length of stay
    was found to have a skewed distribution, and therefore we used the
    Kruskal–Wallis equality-of-populations rank test to compare median
    values.</p>
          <p>When information for the first 400 patients could be evaluated,
    an ad hoc rule was used to trigger an interim analysis by the data
    and safety monitoring board: if more than 66% of cases of
    pancreatitis or bleeding were in a particular study group, a formal
    comparison between groups would be performed with the use of a
    two-sided stopping boundary of 0.005. On the basis of the results of
    the first analysis, the data and safety monitoring board recommended
    a second interim analysis after an additional 200 patients were
    enrolled.</p>
          <p>According to a previously proposed framework for evaluating the
    heterogeneity in treatment effects on the primary end
    point,(<xref alt="Kent et al. 2010" rid="ref-kent2010-nb-article" ref-type="bibr">Kent
    et al. 2010</xref>) a post hoc analysis (not described in the
    protocol) was performed on data from enrolled patients according to
    their pretreatment risk of post-ERCP pancreatitis. In this analysis,
    we assessed whether the relative treatment effect was consistent
    across the spectrum of risk of post-ERCP pancreatitis. Individual
    patient risk scores were determined by assigning one point for each
    major inclusion criterion and 0.5 points for each minor inclusion
    criterion.</p>
          <p>We performed additional exploratory subgroup analyses on the
    following prespecified characteristics: age, sex, suspicion of
    sphincter of Oddi dysfunction, a history of post-ERCP pancreatitis,
    a history of recurrent pancreatitis, sphincter of Oddi dysfunction
    as documented on manometry, more than eight cannulation attempts,
    precut sphincterotomy, pancreatic sphincterotomy, pancreatic
    acinarization, biliary sphincterotomy, ampullectomy, placement of a
    pancreatic stent, and trainee involvement in the ERCP. We performed
    additional post hoc subgroup analyses on the type of sphincter of
    Oddi dysfunction, inpatient versus outpatient status, and
    participating medical center. All subgroup statistical analyses were
    evaluated for interaction effects with indomethacin by testing for
    significance of a corresponding interaction term in a multiple
    logistic-regression
    model.(<xref alt="Kent et al. 2010" rid="ref-kent2010-nb-article" ref-type="bibr">Kent
    et al. 2010</xref>)</p>
        </sec>
      </sec>
      <sec id="results-nb-article">
        <title>Results</title>
        <sec id="patients-1-nb-article">
          <title>Patients</title>
          <p>From February 2009 through July 2011, a total of 602 subjects
    were enrolled
    (<xref alt="Figure 1" rid="fig-enrollment-outcomes-nb-article">Figure 1</xref>).
    In July 2011, the data and safety monitoring board performed an
    interim analysis to assess the outcomes of the first 600 patients
    and recommended that the study be terminated early on the basis of
    the benefit of indomethacin as compared with placebo. Thus, we
    terminated the study according to the a priori stopping rule.</p>
          <sec id="cell-fig-enrollment-outcomes-nb-article" specific-use="notebook-code">
            <code language="python"># use https://github.com/adayim/consort 
# use the consort package to generate a CONSORT diagram using the indo_rct dataset, much like the picture below
N &lt;- 799
trialno &lt;- sample(c(1000:2000), N)
exc1 &lt;- rep(NA, N)
exc1[sample(1:N, 197)] &lt;- sample(c("Did not meet inclusion criteria", "Met exclusion criteria", "Did not undergo ERCP"),  15, replace = TRUE, prob = c(0.858, 0.0558, 0.086))</code>
            <sec id="cell-fig-enrollment-outcomes-output-0-nb-article" specific-use="notebook-output">
              <preformat>Warning in exc1[sample(1:N, 197)] &lt;- sample(c("Did not meet inclusion
criteria", : number of items to replace is not a multiple of replacement lengthWarning in rm(trialno, exc1, induc, exc2, exc1, arm, arm3, N): object 'exc1'
not found</preformat>
            </sec>
            <sec id="cell-fig-enrollment-outcomes-output-1-nb-article" specific-use="notebook-output">
              <fig id="fig-enrollment-outcomes-nb-article">
                <caption>
                  <p>Figure 1: Enrollment and Outcomes.</p>
                </caption>
                <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/notebooks-consort-fig-enrollment-outcomes-output-2.png"/>
              </fig>
            </sec>
          </sec>
          <sec id="nb-code-cell-2-nb-article" specific-use="notebook-code">
            <code language="r script">indo_rct_rx &lt;- indo_rct |&gt;
  count(rx)

n_indomethacin &lt;- indo_rct_rx |&gt;
  filter(rx == "1_indomethacin") |&gt;
  pull(n)

n_placebo &lt;- indo_rct_rx |&gt;
  filter(rx == "0_placebo") |&gt;
  pull(n)</code>
          </sec>
          <sec id="nb-code-cell-3-nb-article" specific-use="notebook-code">
            <code language="r script">p_oddi &lt;- indo_rct |&gt; 
  mutate(type = if_else(type != "0_no SOD", "oddi", "no oddi")) |&gt;
  count(type) |&gt;
  mutate(p = round(n / sum(n) * 100, 1)) |&gt;
  filter(type == "oddi") |&gt;
  pull(p)</code>
          </sec>
          <p>A total of 295 patients received indomethacin, and 307 patients
    received placebo. One patient in the indomethacin group could not
    retain the suppositories but was included in the intention-to-treat
    analysis. Follow-up of all patients for the primary and secondary
    end points was complete
    (<xref alt="Figure 1" rid="fig-enrollment-outcomes-nb-article">Figure 1</xref>).
    Baseline characteristics were similar in the two study groups
    (<xref alt="Table 1" rid="tbl-characteristics-baseline-nb-article">Table 1</xref>).
    Notably, 82.2% of patients had a clinical suspicion of sphincter of
    Oddi dysfunction.</p>
          <sec id="nb-code-cell-4-nb-article" specific-use="notebook-code">
            <code language="r script"># reproduction of https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2012/nejm_2012.366.issue-15/nejmoa1111103/production/images/img_medium/nejmoa1111103_t1.jpeg
tbl_summary(
  indo_rct,
  include = c("age", "gender", "sod", "pep", "recpanc", "difcan", "precut", "paninj", "psphinc", "acinar", "bsphinc", "amp", "pdstent", "train"),
   by = rx,
  missing = "no"
)   |&gt;
  add_n() |&gt; # add column with total number of non-missing observations
  add_p() |&gt; # test for a difference between groups
  modify_header(label = "**Variable**") |&gt; # update the column header
  bold_labels()</code>
            <fig id="tbl-characteristics-baseline-nb-article">
              <caption>
                <p>Table 1: Characteristics of the Patients at
      Baseline.</p>
              </caption>
            </fig>
          </sec>
        </sec>
        <sec id="study-outcomes-nb-article">
          <title>Study outcomes</title>
          <p>The primary outcome of post-ERCP pancreatitis occurred in 79 of
    602 patients (13.1%). Of these events, 27 of 295 (9.2%) occurred in
    the indomethacin group and 52 of 307 (16.9%) occurred in the placebo
    group (P=0.005), corresponding to an absolute risk reduction of 7.7
    percentage points (number needed to treat [NNT] to prevent one
    episode of post-ERCP pancreatitis, 13) and a relative risk reduction
    of 46%
    (<xref alt="Figure 2" rid="fig-incidences-adverse-events-nb-article">Figure 2</xref>).</p>
          <sec id="cell-fig-incidences-adverse-events-nb-article" specific-use="notebook-code">
            <code language="python"># A - moderate to severe missing
plot_a &lt;- indo_rct |&gt; 
  count(rx, outcome) |&gt;
  group_by(rx) |&gt;
  mutate(p = n / sum(n)) |&gt;
  filter(outcome == "1_yes") |&gt;
  ungroup() |&gt;
  mutate(
    rx = case_match(
      rx, 
      "0_placebo" ~ "Placebo",
      "1_indomethacin" ~ "Indomethacin"
    ),
    rx = fct_relevel(rx, "Placebo", "Indomethacin"),
    p = p*100
  ) |&gt;
  ggplot(aes(x = rx, y = p, fill = rx)) +
  geom_col(color = "black") +
  scale_fill_manual(
    values = c(
      "Placebo" = "azure2", 
      "Indomethacin" =  "deepskyblue4"
    )
  ) + 
  theme_classic() +
  theme(
    legend.position = "top",
    axis.text.x = element_blank(),
    axis.ticks.x = element_blank()
  ) +
  ylim(0, 20) +
  labs(
    x = "All Post-ERCP\nPancreatitis",
    y = "Patients (%)",
    fill = NULL
  )

# renal failure missing
plot_b &lt;- indo_rct |&gt;
  filter(bleed == 1) |&gt;
  mutate(
    rx = case_match(
      rx, 
      "0_placebo" ~ "Placebo",
      "1_indomethacin" ~ "Indomethacin"
      ),
    rx = fct_relevel(rx, "Placebo", "Indomethacin")
  ) |&gt;
  count(rx, bleed) |&gt;
  ggplot(aes(x = rx, y = n, fill = rx)) +
  geom_col(color = "black") +
  scale_fill_manual(
    values = c(
      "Placebo" = "azure2", 
      "Indomethacin" =  "deepskyblue4"
    )
  ) + 
  theme_classic() +
  theme(
    legend.position = "top",
    axis.text.x = element_blank(),
    axis.ticks.x = element_blank()
  ) +
  ylim(0, 8) +
  labs(
    x = "Gastrointestinal\nBleeding",
    y = "No. of Adverse Events",
    fill = NULL
  )

plot_a + plot_b</code>
            <sec id="cell-fig-incidences-adverse-events-output-0-nb-article" specific-use="notebook-output">
              <fig id="fig-incidences-adverse-events-nb-article">
                <caption>
                  <p>Figure 2: Incidence of the Primary and Secondary End
      Points and Adverse Events</p>
                </caption>
                <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/notebooks-incidences-fig-incidences-adverse-events-output-1.png"/>
              </fig>
            </sec>
          </sec>
          <p>All 79 patients with post-ERCP pancreatitis completed the 30-day
    follow-up necessary to determine the severity of post-ERCP
    pancreatitis. The secondary outcome of moderate or severe post-ERCP
    pancreatitis occurred in 40 patients: 13 (4.4%) in the indomethacin
    group and 27 (8.8%) in the placebo group (P=0.03)
    (<xref alt="Figure 2" rid="fig-incidences-adverse-events-nb-article">Figure 2</xref>).
    Three patients in each group had severe post-ERCP pancreatitis, and
    one patient in the placebo group had pancreatic necrosis.</p>
          <p>Among patients with post-ERCP pancreatitis, the median length of
    hospital stay was 0.5 days shorter in the indomethacin group than in
    the placebo group (3.5 vs. 4.0 days, P&lt;0.001).</p>
          <sec id="heterogeneity-in-treatment-effects-nb-article">
            <title>Heterogeneity in Treatment Effects</title>
            <p>The relative benefit of indomethacin did not vary significantly
      according to patients’ pretreatment risk score, although the
      absolute risk reduction varied from an NNT of 21 for those with a
      risk score of 1 (one major or two minor inclusion criteria) to an
      NNT of 6 for those with a risk score of 5 (e.g., four major and
      two minor inclusion criteria)
      (<xref alt="Figure 3" rid="fig-heterogeneity-nb-article">Figure 3</xref>).</p>
            <fig id="fig-heterogeneity-nb-article">
              <caption>
                <p>Figure 3: Analysis of the Heterogeneity in Treatment
        Effects.</p>
              </caption>
              <graphic mimetype="image" mime-subtype="png" xlink:href="images/clipboard-2828008318.png"/>
            </fig>
          </sec>
        </sec>
        <sec id="exploratory-subgroup-analyses-nb-article">
          <title>Exploratory Subgroup Analyses</title>
          <p>The beneficial effect of indomethacin on the primary outcome was
    also consistent across the other prespecified and post hoc secondary
    subgroups
    (<xref alt="Figure 4" rid="fig-exploratory-subgroup-nb-article">Figure 4</xref>).
    In particular, indomethacin appeared to be protective regardless of
    whether patients had undergone pancreatic stenting or had a clinical
    suspicion of sphincter of Oddi dysfunction; indomethacin was also
    protective in all three subtypes of sphincter of Oddi dysfunction
    and in the two study sites enrolling the largest number of
    patients.</p>
          <fig id="fig-exploratory-subgroup-nb-article">
            <caption>
              <p>Figure 4: Exploratory Subgroup Analyses</p>
            </caption>
            <graphic mimetype="image" mime-subtype="png" xlink:href="images/clipboard-1822931444.png"/>
          </fig>
        </sec>
        <sec id="adverse-events-1-nb-article">
          <title>Adverse Events</title>
          <p>There were 13 adverse events that were potentially attributable
    to the study intervention
    (<xref alt="Figure 2" rid="fig-incidences-adverse-events-nb-article">Figure 2</xref>).
    Clinically significant bleeding occurred in 11 patients (1.8%): 4 in
    the indomethacin group and 7 in the placebo group (P=0.72). None of
    the bleeding events resulted in transfusion of more than 2 units of
    packed red cells or required angiography or surgery for treatment.
    Two cases of acute renal failure occurred, both in the placebo
    group. There were no myocardial infarctions, strokes, or deaths at
    30-day follow-up.</p>
        </sec>
      </sec>
      <sec id="discussion-nb-article">
        <title>Discussion</title>
        <p>Our findings showed that one dose of rectal indomethacin given
  immediately after ERCP significantly reduced the incidence of
  post-ERCP pancreatitis in patients at elevated risk for this
  complication. Moreover, we found that prophylactic indomethacin
  decreased the severity of post-ERCP pancreatitis and was associated
  with a shorter hospital stay. In this trial, the number of high-risk
  ERCP patients who would need to be treated to prevent one episode of
  pancreatitis was 13.</p>
        <p>The majority of patients in this study had a clinical suspicion of
  sphincter of Oddi dysfunction, and more than half had sphincter
  hypertension, as documented on manometry, which suggests that the
  results are particularly applicable to this challenging patient
  population. However, among patients who received indomethacin, there
  was a trend toward benefit with respect to rates of post-ERCP
  pancreatitis for those who did not have a clinical suspicion of
  sphincter of Oddi dysfunction (8.5% vs. 20.0%, P=0.11). Moreover, in a
  subgroup analysis, the relative treatment effect of indomethacin was
  consistent across the spectrum of patients’ risk of post-ERCP
  pancreatitis. Additional studies will be necessary to reproduce our
  results in different patient populations and to determine whether
  indomethacin is effective in low-risk patients, as suggested by our
  previous
  meta-analysis.(<xref alt="Andriulli et al. 2007" rid="ref-andriulli2007-nb-article" ref-type="bibr">Andriulli
  et al. 2007</xref>)</p>
        <p>Although more than 80% of the patients in this clinical trial
  underwent pancreatic stenting on the basis of their elevated risk of
  post-ERCP pancreatitis, certain patients did not receive stents,
  either because the endoscopist did not deem it indicated (e.g.,
  difficult cannulation not requiring a precut sphincterotomy) or
  because placement was not technically feasible (failed pancreatic
  access). Among patients who received a pancreatic stent, indomethacin
  reduced the risk of post-ERCP pancreatitis from 16.1% to 9.7%
  (P=0.04). Indomethacin conferred similar benefit in patients who did
  not receive a pancreatic stent, reducing the risk of post-ERCP
  pancreatitis from 20.6% to 6.3% (P=0.049).</p>
        <p>Congruent with previous clinical trials evaluating NSAIDs in the
  prevention of post-ERCP pancreatitis, the risk of adverse events that
  were potentially attributable to indomethacin in this study was
  similar in the two study groups. Specifically, there was no
  significant between-group difference in the frequency or severity of
  bleeding events. This finding is consistent with previously published
  data suggesting that NSAIDs in standard doses do not increase the risk
  of bleeding after biliary
  sphincterotomy.(<xref alt="Martin L. Freeman et al. 1996" rid="ref-freeman1996-nb-article" ref-type="bibr">Martin
  L. Freeman et al. 1996</xref>;
  <xref alt="Nelson and Freeman 1994" rid="ref-nelson1994major-nb-article" ref-type="bibr">Nelson
  and Freeman 1994</xref>) Of note, patients with contraindications to
  NSAIDs, such as renal failure and active peptic-ulcer disease, were
  excluded from this study.</p>
        <p>The rate of post-ERCP pancreatitis in the placebo group (16.9%)
  exceeded that revealed by the internal audit of high-risk ERCP
  patients at participating institutions (16.9% vs. 10%). (These audit
  results had been used to calculate the sample size.) This difference
  may be due to the increased capture of complications that occurs in
  randomized, controlled trials. Nevertheless, the incidence of
  post-ERCP pancreatitis in the placebo group of this trial was similar
  to that in previous studies of NSAID pharmacoprevention in high-risk
  subjects, in which the mean rate of post-ERCP pancreatitis was
  18.8%.(<xref alt="Andriulli et al. 2007" rid="ref-andriulli2007-nb-article" ref-type="bibr">Andriulli
  et al. 2007</xref>)</p>
        <p>In summary, prophylactic rectal indomethacin significantly reduced
  the incidence and severity of post-ERCP pancreatitis in patients at
  elevated risk for this complication, particularly in those with a
  clinical suspicion of sphincter of Oddi dysfunction.</p>
      </sec>
    </body>
    <back>
      <ref-list>
        <title/>
        <ref id="ref-freeman2004-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Freeman</surname>
                <given-names>Martin L</given-names>
              </name>
              <name>
                <surname>Guda</surname>
                <given-names>Nalini M</given-names>
              </name>
            </person-group>
            <article-title>Prevention of post-ERCP pancreatitis: a comprehensive review</article-title>
            <source>Gastrointestinal Endoscopy</source>
            <year iso-8601-date="2004-06">2004</year>
            <month>06</month>
            <volume>59</volume>
            <issue>7</issue>
            <uri>http://dx.doi.org/10.1016/S0016-5107(04)00353-0</uri>
            <pub-id pub-id-type="doi">10.1016/s0016-5107(04)00353-0</pub-id>
            <fpage>845</fpage>
            <lpage>864</lpage>
          </element-citation>
        </ref>
        <ref id="ref-freeman1996-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Freeman</surname>
                <given-names>Martin L.</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>Douglas B.</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>Stuart</given-names>
              </name>
              <name>
                <surname>Haber</surname>
                <given-names>Gregory B.</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>Mary E.</given-names>
              </name>
              <name>
                <surname>Dorsher</surname>
                <given-names>Paul J.</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>Joseph P.</given-names>
              </name>
              <name>
                <surname>Fennerty</surname>
                <given-names>M. Brian</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>Michael E.</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>Michael J.</given-names>
              </name>
              <name>
                <surname>Lande</surname>
                <given-names>Jeffrey D.</given-names>
              </name>
              <name>
                <surname>Pheley</surname>
                <given-names>Alfred M.</given-names>
              </name>
            </person-group>
            <article-title>Complications of Endoscopic Biliary Sphincterotomy</article-title>
            <source>New England Journal of Medicine</source>
            <year iso-8601-date="1996-09-26">1996</year>
            <month>09</month>
            <day>26</day>
            <volume>335</volume>
            <issue>13</issue>
            <uri>http://dx.doi.org/10.1056/NEJM199609263351301</uri>
            <pub-id pub-id-type="doi">10.1056/nejm199609263351301</pub-id>
            <fpage>909</fpage>
            <lpage>919</lpage>
          </element-citation>
        </ref>
        <ref id="ref-hcupnet2019utilization-nb-article">
          <element-citation>
            <person-group person-group-type="author">
              <name>
                <surname>HCUPnet</surname>
                <given-names>Healthcare Cost</given-names>
              </name>
            </person-group>
            <article-title>Utilization project. Rockville, MD: Agency for healthcare research and quality, 2016</article-title>
            <year iso-8601-date="2019">2019</year>
          </element-citation>
        </ref>
        <ref id="ref-gross1993inflammatory-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Gross</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Leser</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Heinisch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schölmerich</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory mediators and cytokines–new aspects of the pathophysiology and assessment of severity of acute pancreatitis?</article-title>
            <source>Hepato-gastroenterology</source>
            <year iso-8601-date="1993">1993</year>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>522</fpage>
            <lpage>530</lpage>
          </element-citation>
        </ref>
        <ref id="ref-makela1997inhibition-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mäkelä</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuusi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schröder</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro</article-title>
            <source>Scandinavian journal of clinical and laboratory investigation</source>
            <publisher-name>Taylor &amp; Francis</publisher-name>
            <year iso-8601-date="1997">1997</year>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>401</fpage>
            <lpage>407</lpage>
          </element-citation>
        </ref>
        <ref id="ref-murray2003diclofenac-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Murray</surname>
                <given-names>Bill</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>Ross</given-names>
              </name>
              <name>
                <surname>Imrie</surname>
                <given-names>Clem</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>Susan</given-names>
              </name>
              <name>
                <surname>O’suilleabhain</surname>
                <given-names>Criostoir</given-names>
              </name>
            </person-group>
            <article-title>Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography</article-title>
            <source>Gastroenterology</source>
            <publisher-name>Elsevier</publisher-name>
            <year iso-8601-date="2003">2003</year>
            <volume>124</volume>
            <issue>7</issue>
            <fpage>1786</fpage>
            <lpage>1791</lpage>
          </element-citation>
        </ref>
        <ref id="ref-sotoudehmanesh2007indomethacin-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Sotoudehmanesh</surname>
                <given-names>Rasoul</given-names>
              </name>
              <name>
                <surname>Khatibian</surname>
                <given-names>Morteza</given-names>
              </name>
              <name>
                <surname>Kolahdoozan</surname>
                <given-names>Shadi</given-names>
              </name>
              <name>
                <surname>Ainechi</surname>
                <given-names>Sanaz</given-names>
              </name>
              <name>
                <surname>Malboosbaf</surname>
                <given-names>Ramin</given-names>
              </name>
              <name>
                <surname>Nouraie</surname>
                <given-names>Mehdi</given-names>
              </name>
            </person-group>
            <article-title>Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP</article-title>
            <source>Official journal of the American College of Gastroenterology| ACG</source>
            <publisher-name>LWW</publisher-name>
            <year iso-8601-date="2007">2007</year>
            <volume>102</volume>
            <issue>5</issue>
            <fpage>978</fpage>
            <lpage>983</lpage>
          </element-citation>
        </ref>
        <ref id="ref-khoshbaten2008role-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Khoshbaten</surname>
                <given-names>Manouchehr</given-names>
              </name>
              <name>
                <surname>Khorram</surname>
                <given-names>Homayoun</given-names>
              </name>
              <name>
                <surname>Madad</surname>
                <given-names>Leili</given-names>
              </name>
              <name>
                <surname>Ehsani Ardakani</surname>
                <given-names>Mohammad Javad</given-names>
              </name>
              <name>
                <surname>Farzin</surname>
                <given-names>Haleh</given-names>
              </name>
              <name>
                <surname>Zali</surname>
                <given-names>Mohammmad Reza</given-names>
              </name>
            </person-group>
            <article-title>Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis</article-title>
            <source>Journal of gastroenterology and hepatology</source>
            <publisher-name>Wiley Online Library</publisher-name>
            <year iso-8601-date="2008">2008</year>
            <volume>23</volume>
            <issue>7pt2</issue>
            <fpage>e11</fpage>
            <lpage>e16</lpage>
          </element-citation>
        </ref>
        <ref id="ref-je2007effect-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>JE</surname>
                <given-names>Garcı́a Correa</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes</article-title>
            <source>Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva</source>
            <year iso-8601-date="2007">2007</year>
            <volume>99</volume>
            <issue>6</issue>
            <fpage>330</fpage>
            <lpage>336</lpage>
          </element-citation>
        </ref>
        <ref id="ref-elmunzer2008-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Elmunzer</surname>
                <given-names>B J</given-names>
              </name>
              <name>
                <surname>Waljee</surname>
                <given-names>A K</given-names>
              </name>
              <name>
                <surname>Elta</surname>
                <given-names>G H</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>J R</given-names>
              </name>
              <name>
                <surname>Fehmi</surname>
                <given-names>S M A</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>P D R</given-names>
              </name>
            </person-group>
            <article-title>A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis</article-title>
            <source>Gut</source>
            <year iso-8601-date="2008-03-28">2008</year>
            <month>03</month>
            <day>28</day>
            <volume>57</volume>
            <issue>9</issue>
            <uri>http://dx.doi.org/10.1136/gut.2007.140756</uri>
            <pub-id pub-id-type="doi">10.1136/gut.2007.140756</pub-id>
            <fpage>1262</fpage>
            <lpage>1267</lpage>
          </element-citation>
        </ref>
        <ref id="ref-tarnasky1998-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Tarnasky</surname>
                <given-names>Paul R.</given-names>
              </name>
              <name>
                <surname>Palesch</surname>
                <given-names>Yuko Y.</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>John T.</given-names>
              </name>
              <name>
                <surname>Mauldin</surname>
                <given-names>Patrick D.</given-names>
              </name>
              <name>
                <surname>Cotton</surname>
                <given-names>Peter B.</given-names>
              </name>
              <name>
                <surname>Hawes</surname>
                <given-names>Robert H.</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction</article-title>
            <source>Gastroenterology</source>
            <year iso-8601-date="1998-12">1998</year>
            <month>12</month>
            <volume>115</volume>
            <issue>6</issue>
            <uri>http://dx.doi.org/10.1016/S0016-5085(98)70031-9</uri>
            <pub-id pub-id-type="doi">10.1016/s0016-5085(98)70031-9</pub-id>
            <fpage>1518</fpage>
            <lpage>1524</lpage>
          </element-citation>
        </ref>
        <ref id="ref-fazel2003-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Fazel</surname>
                <given-names>Ali</given-names>
              </name>
              <name>
                <surname>Quadri</surname>
                <given-names>Affan</given-names>
              </name>
              <name>
                <surname>Catalano</surname>
                <given-names>Marc F.</given-names>
              </name>
              <name>
                <surname>Meyerson</surname>
                <given-names>Scott M.</given-names>
              </name>
              <name>
                <surname>Geenen</surname>
                <given-names>Joseph E.</given-names>
              </name>
            </person-group>
            <article-title>Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study</article-title>
            <source>Gastrointestinal Endoscopy</source>
            <year iso-8601-date="2003-03">2003</year>
            <month>03</month>
            <volume>57</volume>
            <issue>3</issue>
            <uri>http://dx.doi.org/10.1067/mge.2003.124</uri>
            <pub-id pub-id-type="doi">10.1067/mge.2003.124</pub-id>
            <fpage>291</fpage>
            <lpage>294</lpage>
          </element-citation>
        </ref>
        <ref id="ref-singh2004-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Singh</surname>
                <given-names>Pankaj</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>Ananya</given-names>
              </name>
              <name>
                <surname>Isenberg</surname>
                <given-names>Gerard</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>Richard C. K.</given-names>
              </name>
              <name>
                <surname>Sivak</surname>
                <given-names>Michael V.</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>Deepak</given-names>
              </name>
              <name>
                <surname>Chak</surname>
                <given-names>Amitabh</given-names>
              </name>
            </person-group>
            <article-title>Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials</article-title>
            <source>Gastrointestinal Endoscopy</source>
            <year iso-8601-date="2004-10">2004</year>
            <month>10</month>
            <volume>60</volume>
            <issue>4</issue>
            <uri>http://dx.doi.org/10.1016/S0016-5107(04)02013-9</uri>
            <pub-id pub-id-type="doi">10.1016/s0016-5107(04)02013-9</pub-id>
            <fpage>544</fpage>
            <lpage>550</lpage>
          </element-citation>
        </ref>
        <ref id="ref-dumonceau2010-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Dumonceau</surname>
                <given-names>Jean-Marc</given-names>
              </name>
              <name>
                <surname>Rigaux</surname>
                <given-names>Johanne</given-names>
              </name>
              <name>
                <surname>Kahaleh</surname>
                <given-names>Michel</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>Carlos Macias</given-names>
              </name>
              <name>
                <surname>Vandermeeren</surname>
                <given-names>Alain</given-names>
              </name>
              <name>
                <surname>Devière</surname>
                <given-names>Jacques</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis of post-ERCP pancreatitis: a practice survey</article-title>
            <source>Gastrointestinal Endoscopy</source>
            <year iso-8601-date="2010-05">2010</year>
            <month>05</month>
            <volume>71</volume>
            <issue>6</issue>
            <uri>http://dx.doi.org/10.1016/j.gie.2009.10.055</uri>
            <pub-id pub-id-type="doi">10.1016/j.gie.2009.10.055</pub-id>
            <fpage>934</fpage>
            <lpage>939.e2</lpage>
          </element-citation>
        </ref>
        <ref id="ref-andriulli2000-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Andriulli</surname>
                <given-names>Angelo</given-names>
              </name>
              <name>
                <surname>Leandro</surname>
                <given-names>Gioacchino</given-names>
              </name>
              <name>
                <surname>Niro</surname>
                <given-names>Grazia</given-names>
              </name>
              <name>
                <surname>Mangia</surname>
                <given-names>Alessandra</given-names>
              </name>
              <name>
                <surname>Festa</surname>
                <given-names>Virginia</given-names>
              </name>
              <name>
                <surname>Gambassi</surname>
                <given-names>Giovanni</given-names>
              </name>
              <name>
                <surname>Villani</surname>
                <given-names>Maria Rosaria</given-names>
              </name>
              <name>
                <surname>Facciorusso</surname>
                <given-names>Domenico</given-names>
              </name>
              <name>
                <surname>Conoscitore</surname>
                <given-names>Pasquale</given-names>
              </name>
              <name>
                <surname>Spirito</surname>
                <given-names>Fulvio</given-names>
              </name>
              <name>
                <surname>De Maio</surname>
                <given-names>Giovanni</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis</article-title>
            <source>Gastrointestinal Endoscopy</source>
            <year iso-8601-date="2000-01">2000</year>
            <month>01</month>
            <volume>51</volume>
            <issue>1</issue>
            <uri>http://dx.doi.org/10.1016/S0016-5107(00)70377-4</uri>
            <pub-id pub-id-type="doi">10.1016/s0016-5107(00)70377-4</pub-id>
            <fpage>1</fpage>
            <lpage>7</lpage>
          </element-citation>
        </ref>
        <ref id="ref-andriulli2007-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Andriulli</surname>
                <given-names>Angelo</given-names>
              </name>
              <name>
                <surname>Leandro</surname>
                <given-names>Gioacchino</given-names>
              </name>
              <name>
                <surname>Federici</surname>
                <given-names>Telemaco</given-names>
              </name>
              <name>
                <surname>Ippolito</surname>
                <given-names>Antonio</given-names>
              </name>
              <name>
                <surname>Forlano</surname>
                <given-names>Rosario</given-names>
              </name>
              <name>
                <surname>Iacobellis</surname>
                <given-names>Angelo</given-names>
              </name>
              <name>
                <surname>Annese</surname>
                <given-names>Vito</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis</article-title>
            <source>Gastrointestinal Endoscopy</source>
            <year iso-8601-date="2007-04">2007</year>
            <month>04</month>
            <volume>65</volume>
            <issue>4</issue>
            <uri>http://dx.doi.org/10.1016/j.gie.2006.10.030</uri>
            <pub-id pub-id-type="doi">10.1016/j.gie.2006.10.030</pub-id>
            <fpage>624</fpage>
            <lpage>632</lpage>
          </element-citation>
        </ref>
        <ref id="ref-freeman2007-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Freeman</surname>
                <given-names>Martin L.</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic Stents for Prevention of PostEndoscopic Retrograde Cholangiopancreatography Pancreatitis</article-title>
            <source>Clinical Gastroenterology and Hepatology</source>
            <year iso-8601-date="2007-11">2007</year>
            <month>11</month>
            <volume>5</volume>
            <issue>11</issue>
            <uri>http://dx.doi.org/10.1016/j.cgh.2007.09.007</uri>
            <pub-id pub-id-type="doi">10.1016/j.cgh.2007.09.007</pub-id>
            <fpage>1354</fpage>
            <lpage>1365</lpage>
          </element-citation>
        </ref>
        <ref id="ref-vandermarel2004-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Marel</surname>
                <given-names>Caroline D. van der</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>Brian J.</given-names>
              </name>
              <name>
                <surname>Rømsing</surname>
                <given-names>Janne</given-names>
              </name>
              <name>
                <surname>Jacqz-Aigrain</surname>
                <given-names>Evelyne</given-names>
              </name>
              <name>
                <surname>Tibboel</surname>
                <given-names>Dick</given-names>
              </name>
            </person-group>
            <article-title>Diclofenac and metabolite pharmacokinetics in children</article-title>
            <source>Pediatric Anesthesia</source>
            <year iso-8601-date="2004-05-20">2004</year>
            <month>05</month>
            <day>20</day>
            <volume>14</volume>
            <issue>6</issue>
            <uri>http://dx.doi.org/10.1111/j.1460-9592.2004.01232.x</uri>
            <pub-id pub-id-type="doi">10.1111/j.1460-9592.2004.01232.x</pub-id>
            <fpage>443</fpage>
            <lpage>451</lpage>
          </element-citation>
        </ref>
        <ref id="ref-cotton1991-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Cotton</surname>
                <given-names>P. B.</given-names>
              </name>
              <name>
                <surname>Lehman</surname>
                <given-names>G.</given-names>
              </name>
              <name>
                <surname>Vennes</surname>
                <given-names>J.</given-names>
              </name>
              <name>
                <surname>Geenen</surname>
                <given-names>J. E.</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>R. C. G.</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>W. C.</given-names>
              </name>
              <name>
                <surname>Liguory</surname>
                <given-names>C.</given-names>
              </name>
              <name>
                <surname>Nickl</surname>
                <given-names>N.</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic sphincterotomy complications and their management: an attempt at consensus</article-title>
            <source>Gastrointestinal Endoscopy</source>
            <year iso-8601-date="1991-05">1991</year>
            <month>05</month>
            <volume>37</volume>
            <issue>3</issue>
            <uri>http://dx.doi.org/10.1016/S0016-5107(91)70740-2</uri>
            <pub-id pub-id-type="doi">10.1016/s0016-5107(91)70740-2</pub-id>
            <fpage>383</fpage>
            <lpage>393</lpage>
          </element-citation>
        </ref>
        <ref id="ref-mallery2003-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mallery</surname>
                <given-names>J.Shawn</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>Todd H.</given-names>
              </name>
              <name>
                <surname>Dominitz</surname>
                <given-names>Jason A.</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>Jay L.</given-names>
              </name>
              <name>
                <surname>Hirota</surname>
                <given-names>William K.</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>Brian C.</given-names>
              </name>
              <name>
                <surname>Leighton</surname>
                <given-names>Jonathan A.</given-names>
              </name>
              <name>
                <surname>Raddawi</surname>
                <given-names>Hareth M.</given-names>
              </name>
              <name>
                <surname>Varg</surname>
                <given-names>John J.</given-names>
              </name>
              <name>
                <surname>Waring</surname>
                <given-names>J.Patrick</given-names>
              </name>
              <name>
                <surname>Fanelli</surname>
                <given-names>Robert D.</given-names>
              </name>
              <name>
                <surname>Wheeler-Harbough</surname>
                <given-names>Jo</given-names>
              </name>
              <name>
                <surname>Eisen</surname>
                <given-names>Glenn M.</given-names>
              </name>
              <name>
                <surname>Faigel</surname>
                <given-names>Douglas O.</given-names>
              </name>
            </person-group>
            <article-title>Complications of ERCP</article-title>
            <source>Gastrointestinal Endoscopy</source>
            <year iso-8601-date="2003-05">2003</year>
            <month>05</month>
            <volume>57</volume>
            <issue>6</issue>
            <uri>http://dx.doi.org/10.1053/ge.2003.v57.amge030576633</uri>
            <pub-id pub-id-type="doi">10.1053/ge.2003.v57.amge030576633</pub-id>
            <fpage>633</fpage>
            <lpage>638</lpage>
          </element-citation>
        </ref>
        <ref id="ref-kent2010-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Kent</surname>
                <given-names>David M</given-names>
              </name>
              <name>
                <surname>Rothwell</surname>
                <given-names>Peter M</given-names>
              </name>
              <name>
                <surname>Ioannidis</surname>
                <given-names>John PA</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>Doug G</given-names>
              </name>
              <name>
                <surname>Hayward</surname>
                <given-names>Rodney A</given-names>
              </name>
            </person-group>
            <article-title>Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal</article-title>
            <source>Trials</source>
            <year iso-8601-date="2010-08-12">2010</year>
            <month>08</month>
            <day>12</day>
            <volume>11</volume>
            <issue>1</issue>
            <uri>http://dx.doi.org/10.1186/1745-6215-11-85</uri>
            <pub-id pub-id-type="doi">10.1186/1745-6215-11-85</pub-id>
          </element-citation>
        </ref>
        <ref id="ref-nelson1994major-nb-article">
          <element-citation publication-type="article-journal">
            <person-group person-group-type="author">
              <name>
                <surname>Nelson</surname>
                <given-names>Douglas B</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>Martin L</given-names>
              </name>
            </person-group>
            <article-title>Major hemorrhage from endoscopic sphincterotomy: Risk factor analysis</article-title>
            <source>Journal of clinical gastroenterology</source>
            <publisher-name>LWW</publisher-name>
            <year iso-8601-date="1994">1994</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>283</fpage>
            <lpage>287</lpage>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </sub-article>
  <sub-article article-type="notebook" id="nb-3-nb-1">
    <front-stub>
      <title-group>
        <article-title>Incidence of the Primary and Secondary End Points and
Adverse Events</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>Bar plots.</p>
      <sec id="nb-code-cell-1-nb-1" specific-use="notebook-code">
        <code language="r script">library(tidyverse)
</code>
        <code language="r script">library(medicaldata)
library(patchwork)
</code>
        <sec id="nb-code-cell-1-output-0-nb-1" specific-use="notebook-output">
          <preformat>── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
✔ dplyr     1.1.4     ✔ readr     2.1.4
✔ forcats   1.0.0     ✔ stringr   1.5.1
✔ ggplot2   3.5.0     ✔ tibble    3.2.1
✔ lubridate 1.9.3     ✔ tidyr     1.3.1
✔ purrr     1.0.2     
── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
✖ dplyr::filter() masks stats::filter()
✖ dplyr::lag()    masks stats::lag()
ℹ Use the conflicted package (&lt;http://conflicted.r-lib.org/&gt;) to force all conflicts to become errors</preformat>
        </sec>
      </sec>
      <sec id="cell-fig-incidences-adverse-events-nb-1" specific-use="notebook-code">
        <code language="r script">
# A - moderate to severe missing
plot_a &lt;- indo_rct |&gt; 
  count(rx, outcome) |&gt;
  group_by(rx) |&gt;
  mutate(p = n / sum(n)) |&gt;
  filter(outcome == "1_yes") |&gt;
  ungroup() |&gt;
  mutate(
    rx = case_match(
      rx, 
      "0_placebo" ~ "Placebo",
      "1_indomethacin" ~ "Indomethacin"
    ),
    rx = fct_relevel(rx, "Placebo", "Indomethacin"),
    p = p*100
  ) |&gt;
  ggplot(aes(x = rx, y = p, fill = rx)) +
  geom_col(color = "black") +
  scale_fill_manual(
    values = c(
      "Placebo" = "azure2", 
      "Indomethacin" =  "deepskyblue4"
    )
  ) + 
  theme_classic() +
  theme(
    legend.position = "top",
    axis.text.x = element_blank(),
    axis.ticks.x = element_blank()
  ) +
  ylim(0, 20) +
  labs(
    x = "All Post-ERCP\nPancreatitis",
    y = "Patients (%)",
    fill = NULL
  )

# renal failure missing
plot_b &lt;- indo_rct |&gt;
  filter(bleed == 1) |&gt;
  mutate(
    rx = case_match(
      rx, 
      "0_placebo" ~ "Placebo",
      "1_indomethacin" ~ "Indomethacin"
      ),
    rx = fct_relevel(rx, "Placebo", "Indomethacin")
  ) |&gt;
  count(rx, bleed) |&gt;
  ggplot(aes(x = rx, y = n, fill = rx)) +
  geom_col(color = "black") +
  scale_fill_manual(
    values = c(
      "Placebo" = "azure2", 
      "Indomethacin" =  "deepskyblue4"
    )
  ) + 
  theme_classic() +
  theme(
    legend.position = "top",
    axis.text.x = element_blank(),
    axis.ticks.x = element_blank()
  ) +
  ylim(0, 8) +
  labs(
    x = "Gastrointestinal\nBleeding",
    y = "No. of Adverse Events",
    fill = NULL
  )

plot_a + plot_b
</code>
        <fig id="fig-incidences-adverse-events-nb-1">
          <caption>
            <p>Incidence of the Primary and Secondary End Points and
  Adverse Events</p>
          </caption>
          <graphic mimetype="image" mime-subtype="png" xlink:href="incidences_files/figure-jats/fig-incidences-adverse-events-1.png"/>
        </fig>
      </sec>
    </body>
    <back>
</back>
  </sub-article>
  <sub-article article-type="notebook" id="nb-6-nb-2">
    <front-stub>
      <title-group>
        <article-title>Characteristics of the Patients at
Baseline.</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>For Table 1.</p>
      <sec id="nb-code-cell-1-nb-2" specific-use="notebook-code">
        <code language="r script">library(tidyverse)
</code>
        <code language="r script">library(medicaldata)
library(gtsummary)
</code>
        <sec id="nb-code-cell-1-output-0-nb-2" specific-use="notebook-output">
          <preformat>── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
✔ dplyr     1.1.4     ✔ readr     2.1.4
✔ forcats   1.0.0     ✔ stringr   1.5.1
✔ ggplot2   3.5.0     ✔ tibble    3.2.1
✔ lubridate 1.9.3     ✔ tidyr     1.3.1
✔ purrr     1.0.2     
── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
✖ dplyr::filter() masks stats::filter()
✖ dplyr::lag()    masks stats::lag()
ℹ Use the conflicted package (&lt;http://conflicted.r-lib.org/&gt;) to force all conflicts to become errors</preformat>
        </sec>
      </sec>
      <sec id="nb-code-cell-2-nb-2" specific-use="notebook-code">
        <code language="r script">
# reproduction of https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2012/nejm_2012.366.issue-15/nejmoa1111103/production/images/img_medium/nejmoa1111103_t1.jpeg
tbl_summary(
  indo_rct,
  include = c("age", "gender", "sod", "pep", "recpanc", "difcan", "precut", "paninj", "psphinc", "acinar", "bsphinc", "amp", "pdstent", "train"),
   by = rx,
  missing = "no"
)   |&gt;
  add_n() |&gt; # add column with total number of non-missing observations
  add_p() |&gt; # test for a difference between groups
  modify_header(label = "**Variable**") |&gt; # update the column header
  bold_labels()
</code>
        <fig id="tbl-characteristics-baseline-nb-2">
          <caption>
            <p>Characteristics of the Patients at Baseline.</p>
          </caption>
          <table-wrap>
            <table>
              <colgroup>
                <col width="20%"/>
                <col width="20%"/>
                <col width="20%"/>
                <col width="20%"/>
                <col width="20%"/>
              </colgroup>
              <thead>
                <tr>
                  <th id="U003CstrongU003EVariableU003CU002FstrongU003E-nb-2" scope="col">
                    <bold>Variable</bold>
                  </th>
                  <th id="U003CstrongU003ENU003CU002FstrongU003E-nb-2" scope="col">
                    <bold>N</bold>
                  </th>
                  <th id="U003CstrongU003E0_placeboU003CU002FstrongU003EU002CU0020NU0020U003DU0020307U003CspanU0020classU003DU0022gt_footnote_marksU0022U0020styleU003DU0022white-spaceU003AnowrapU003Bfont-styleU003AitalicU003Bfont-weightU003AnormalU003BU0022U003EU003CsupU003E1U003CU002FsupU003EU003CU002FspanU003E-nb-2" scope="col"><bold>0_placebo</bold>,
          N =
          307<named-content content-type="gt_footnote_marks"><sup>1</sup></named-content></th>
                  <th id="U003CstrongU003E1_indomethacinU003CU002FstrongU003EU002CU0020NU0020U003DU0020295U003CspanU0020classU003DU0022gt_footnote_marksU0022U0020styleU003DU0022white-spaceU003AnowrapU003Bfont-styleU003AitalicU003Bfont-weightU003AnormalU003BU0022U003EU003CsupU003E1U003CU002FsupU003EU003CU002FspanU003E-nb-2" scope="col"><bold>1_indomethacin</bold>,
          N =
          295<named-content content-type="gt_footnote_marks"><sup>1</sup></named-content></th>
                  <th id="U003CstrongU003Ep-valueU003CU002FstrongU003EU003CspanU0020classU003DU0022gt_footnote_marksU0022U0020styleU003DU0022white-spaceU003AnowrapU003Bfont-styleU003AitalicU003Bfont-weightU003AnormalU003BU0022U003EU003CsupU003E2U003CU002FsupU003EU003CU002FspanU003E-nb-2" scope="col">
                    <bold>p-value</bold>
                    <named-content content-type="gt_footnote_marks">
                      <sup>2</sup>
                    </named-content>
                  </th>
                </tr>
              </thead>
              <tfoot>
                <tr>
                  <td colspan="5"><named-content content-type="gt_footnote_marks"><sup>1</sup></named-content>
          Median (IQR); n (%)</td>
                </tr>
                <tr>
                  <td colspan="5"><named-content content-type="gt_footnote_marks"><sup>2</sup></named-content>
          Wilcoxon rank sum test; Pearson’s Chi-squared test</td>
                </tr>
              </tfoot>
              <tbody>
                <tr>
                  <td headers="label" style="font-weight: bold">age</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">46 (36, 55)</td>
                  <td headers="stat_2">44 (33, 54)</td>
                  <td headers="p.value">0.2</td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">gender</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.4</td>
                </tr>
                <tr>
                  <td headers="label">    1_female</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">247 (80%)</td>
                  <td headers="stat_2">229 (78%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    2_male</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">60 (20%)</td>
                  <td headers="stat_2">66 (22%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">sod</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.2</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">60 (20%)</td>
                  <td headers="stat_2">47 (16%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">247 (80%)</td>
                  <td headers="stat_2">248 (84%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">pep</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">&gt;0.9</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">258 (84%)</td>
                  <td headers="stat_2">248 (84%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">49 (16%)</td>
                  <td headers="stat_2">47 (16%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">recpanc</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.7</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">213 (69%)</td>
                  <td headers="stat_2">209 (71%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">94 (31%)</td>
                  <td headers="stat_2">86 (29%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">difcan</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.6</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">230 (75%)</td>
                  <td headers="stat_2">215 (73%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">77 (25%)</td>
                  <td headers="stat_2">80 (27%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">precut</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.8</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">290 (94%)</td>
                  <td headers="stat_2">280 (95%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">17 (5.5%)</td>
                  <td headers="stat_2">15 (5.1%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">paninj</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.2</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">271 (88%)</td>
                  <td headers="stat_2">270 (92%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">36 (12%)</td>
                  <td headers="stat_2">25 (8.5%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">psphinc</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.4</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">137 (45%)</td>
                  <td headers="stat_2">122 (41%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">170 (55%)</td>
                  <td headers="stat_2">173 (59%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">acinar</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.5</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">295 (96%)</td>
                  <td headers="stat_2">280 (95%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">12 (3.9%)</td>
                  <td headers="stat_2">15 (5.1%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">bsphinc</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.5</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">136 (44%)</td>
                  <td headers="stat_2">122 (41%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">171 (56%)</td>
                  <td headers="stat_2">173 (59%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">amp</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">&gt;0.9</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">298 (97%)</td>
                  <td headers="stat_2">286 (97%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">9 (2.9%)</td>
                  <td headers="stat_2">9 (3.1%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">pdstent</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.4</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">58 (19%)</td>
                  <td headers="stat_2">48 (16%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">249 (81%)</td>
                  <td headers="stat_2">247 (84%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label" style="font-weight: bold">train</td>
                  <td headers="n">602</td>
                  <td headers="stat_1">
                    <break/>
                  </td>
                  <td headers="stat_2">
                    <break/>
                  </td>
                  <td headers="p.value">0.5</td>
                </tr>
                <tr>
                  <td headers="label">    0_no</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">167 (54%)</td>
                  <td headers="stat_2">152 (52%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
                <tr>
                  <td headers="label">    1_yes</td>
                  <td headers="n">
                    <break/>
                  </td>
                  <td headers="stat_1">140 (46%)</td>
                  <td headers="stat_2">143 (48%)</td>
                  <td headers="p.value">
                    <break/>
                  </td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </fig>
      </sec>
    </body>
    <back>
</back>
  </sub-article>
  <sub-article article-type="notebook" id="nb-9-nb-3">
    <front-stub>
      <title-group>
        <article-title>Enrollment and Outcomes</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>Consort diagram.</p>
      <sec id="nb-code-cell-1-nb-3" specific-use="notebook-code">
        <code language="r script">
library(consort)
</code>
      </sec>
      <sec id="cell-fig-enrollment-outcomes-nb-3" specific-use="notebook-code">
        <code language="r script">
# use https://github.com/adayim/consort 
# use the consort package to generate a CONSORT diagram using the indo_rct dataset, much like the picture below
N &lt;- 799
trialno &lt;- sample(c(1000:2000), N)
exc1 &lt;- rep(NA, N)
exc1[sample(1:N, 197)] &lt;- sample(c("Did not meet inclusion criteria", "Met exclusion criteria", "Did not undergo ERCP"),  15, replace = TRUE, prob = c(0.858, 0.0558, 0.086))
</code>
        <code language="r script">
induc &lt;- rep(NA, N)
induc[is.na(exc1)] &lt;- trialno[is.na(exc1)]

exc2 &lt;- rep(NA, N)
exc2[sample(1:N, 1)] &lt;- sample(c( "Could not hold suppository"), 1, replace = TRUE, prob = c(0.0039))
exc2[is.na(induc)] &lt;- NA

arm &lt;- rep(NA, N)
arm[is.na(exc1)] &lt;- sample(c("Conc", "Seq"), sum(is.na(exc1)), replace = TRUE)
arm3 &lt;- sample(c("Indomethacin", "Placebo"), N, replace = TRUE)
arm3[is.na(arm)] &lt;- NA

df_consort &lt;- data.frame(trialno, exc1, induc, exc2, exc1, arm, arm3)
rm(trialno, exc1, induc, exc2, exc1, arm, arm3, N)
</code>
        <code language="r script">
consort_plot(
  data = df_consort,
  order = list(
  trialno = "Population",
  exc1 = "Excluded",
  induc = "Induction",
  exc2 = "Excluded",
  arm3 = "Randomized patient",
  trialno = "Finished Followup",
  trialno = "Final Analysis"
),
  side_box = c("exc1", "exc2"),
  allocation = "arm3",
  labels = c(
  "1" = "Screening", "2" = "Randomization",
  "3" = "Assignment", "5" = "End of study"
  ),
 cex = 0.7
)
</code>
        <fig id="fig-enrollment-outcomes-nb-3">
          <caption>
            <p>Enrollment and Outcomes.</p>
          </caption>
          <graphic mimetype="image" mime-subtype="png" xlink:href="consort_files/figure-jats/fig-enrollment-outcomes-1.png"/>
        </fig>
        <sec id="cell-fig-enrollment-outcomes-output-0-nb-3" specific-use="notebook-output">
          <preformat>Warning in exc1[sample(1:N, 197)] &lt;- sample(c("Did not meet inclusion
criteria", : number of items to replace is not a multiple of replacement length</preformat>
        </sec>
        <sec id="cell-fig-enrollment-outcomes-output-1-nb-3" specific-use="notebook-output">
          <preformat>Warning in rm(trialno, exc1, induc, exc2, exc1, arm, arm3, N): object 'exc1'
not found</preformat>
        </sec>
      </sec>
    </body>
    <back>
</back>
  </sub-article>
</article>
